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Drug resistant tuberculosis is a major contributor to South Africa’s quadruple burden of 
disease. Management of this infection in a highly HIV endemic area is a constant challenge. 
There is a paucity of new anti-tuberculosis agents in the developmental and clinical trial 
phases to address the problem of extensively-drug resistant tuberculosis (XDR-TB). In an 
attempt to affect a cure in patients with XDR-TB, it has become necessary to re-introduce 
previously used anti-tuberculosis drugs, as well as antimicrobial agents designed for 
treatment of non-tuberculosis infections. Whilst these drugs may have previously been tested 
and shown efficacy in drug susceptible tuberculosis, their activity in XDR TB strains was not 
tested before introduction for management of XDR-TB in KwaZulu-Natal, South Africa. 
Drug susceptibility testing (DST) plays an integral role in the diagnosis and treatment options 
for tuberculosis. It is able to decrease the burden and spread of resistant tuberculosis. 
However DSTs methods for second line anti –TB drugs (SLDs) and third line anti-TB drugs 
(TLDs) have not been standardised. Critical concentrations of these anti-TB drugs remain 
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Previously effective therapeutic strategies to manage tuberculosis (TB) have unfortunately not 
succeeded in eradicating the causative agent, Mycobacterium tuberculosis (MTB). The 
escalating incidence of TB in Africa, in particular amongst the human immunodeficiency 
virus (HIV) type 1 (HIV-1) infected population, coupled with increasing antimicrobial 
resistance, underscores the urgency to address public health interventions and optimise anti-
mycobacterial drug use. HIV is responsible for the highest number of deaths caused by any 
single infectious disease (WHO, 2011a). TB follows closely, and in 2010, the World Health 
Organisation (WHO) revealed that there were 9 million cases of TB globally, which caused 
1.3 million deaths (WHO, 2011a). 
  
Multi drug resistant TB (MDR-TB) is defined as an isolate that is resistant to the two most 
potent first line anti-TB agents, isoniazid (INH) and rifampicin (RIF) (WHO, 2008a). In the 
1990’s, cases  of MDR-TB was reported in New York, Florida and London, (Breathnach et 
al., 1998; Coronado et al., 1993; Edlin et al., 1992; Frieden et al., 1996;) and was attributed to 
delayed diagnosis, inappropriate treatment regimens, non-compliance to therapy and high 
rates of nosocomial transmission (Dooley et al., 1992). At the turn of the century, the extent 
of the spread of MDR-TB was highlighted through reports of its presence in almost 90 
countries and regions worldwide (Shah, et al., 2007). In 2008, 440 000 cases of MDR-TB 
were reported worldwide (WHO, 2010). This however represents the tip of the iceberg with 
large numbers of cases being unreported. The under reporting has been attributed to a 
significant number of cases being either not diagnosed, or incorrectly diagnosed; or if 
diagnosed are not correctly treated. It was also reported that only 20% of cases that were 
diagnosed, were treated according to the accepted international guidelines (Nathanson et al., 
2010). India and China have the highest burden of MDR-TB, and account for almost 50 % of 
the world’s cases (Nathanson et al., 2010). 
 
In 2010, the number of globally reported MDR-TB cases increased to 650 000. This was a 
third more than the figure that was reported in 2008 (WHO, 2011b). In South Africa (SA), the 









KwaZulu-Natal (KZN), MDR-TB strains were traceable as far back as 1994 (Pillay and 
Sturm, 2007). In 2006/2007, the incidence of MDR-TB in KZN was 780 per 100 000 
population, with only 145 per 100 000 being culture confirmed positive, thus indicating that 
over 80 % of reported cases were not culture confirmed and additionally did not have drug 
susceptibility tests (DSTs) performed on them (Moodley et al.,  2011). 
 
The MDR form of MTB further evolved into a more resistant form termed extensively drug 
resistant (XDR-TB). XDR-TB is MDR-TB (resistance to RIF, INH) with additional resistance 
to the fluoroquinolones, plus one of the injectables viz: capreomycin (CAP) and/or kanamycin 
(KAN) and/or amikacin (AMIK) (CDC, 2006; Shah et al., 2005; WHO, 2006a). 
 
XDR-TB was identified as far back as the late 1980’s and early 1990’s in the United States, 
Latvia and Russia (Koening, 2008). By the end of 2004, XDR-TB had spread to17 countries 
in a period of 4 years (Banerjee et al., 2008). In 2008 XDR-TB was reported to be present in 
at least 45 countries (WHO, 2008a). By 2011 XDR-TB was present in 69 countries (WHO, 
2011b). 
 
In 2006, 53 cases of XDR-TB were identified in the Tugela Ferry region of KZN, SA (Gandhi 
et al., 2006). Fifty two (98%) patients died approximately 2 weeks after diagnostic sputum 
collection for detection of TB. Forty- four (83%) were co-infected with HIV (Gandhi et al., 
2006). Whilst the first clinical case of XDR-TB was reported in 2006 in KZN, an analysis of 
the TB isolate bank in KZN revealed that the XDR form of the microbe was present in KZN 
from as early as 2001 (Pillay and Sturm, 2007). India, China, Russia and South Africa, have 
the largest number of cases of drug resistant TB (DR-TB), and these countries are home to 
more than half the world’s cases of DR-TB (WHO, 2012b).  
 
In 2007, the first report of totally drug resistant strains of TB (TDR-TB) was reported in Italy 
(Migliori et al., 2007). Further reports of TDR-TB then followed in Iran (Velayati et al., 
2009) and India (Udwadia et al., 2011). TDR-TB refers to MTB that is resistant to all first 
line anti-TB drugs (FLD) and all second line anti-TB drugs (SLD). Infection with these strains 










Various factors aid in the development of drug resistance. These include poor treatment 
compliance, HIV co-infection and poverty (Thaver and Ogunbanjo, 2007). In vivo drug 
resistance involves complex interactions between the organism, site of infection and the 
pharmacokinetic (PK) and pharmacodynamic (PD) properties of the drug (Kim, 2005). De-
novo resistance was observed initially among TB patients that received sub-optimal drug 
treatment (Pillay and Sturm, 2007). Inadequate and inappropriate treatment has been 
attributed as being primarily responsible for de novo drug resistance (Kim, 2005 ; Pillay and 
Sturm, 2007). 
 
The observation that already resistant strains of TB (MDR including XDR and TDR) are now 
being isolated from newly diagnosed TB patients supports transmission of already resistant 
strains within the community (Pillay and Sturm, 2007 ; Ramtahal et al., 2012) . 
 
The treatment of DR-TB remains a challenge. WHO classifies the SLDs used for treatment of 
MDR-TB into 5 classes (WHO, 2008b). In KZN, MDR-TB patients were treated with SLDs 
viz: AMIK or KAN and ofloxacin. The emergence of XDR-TB prompted health officials to 
look at alternatives. In 2007, CAP and para-aminosalicylic acid (PAS) were re-introduced in 
SA as SLD for the management of patients with XDR-TB (Dheda et al., 2010; Master, 2011). 
In addition, antimicrobial agents viz: linezolid (LIN) and imipenam (IMI) that were already 
being used for the management of non-mycobacterial infections were reported as showing in 
vitro activity against DR-MTB (Anger et al., 2010; Migliori et al., 2009). Meropenam (in the 
same carbapenam class as imipenam) in combination with clavulanic acid (M&C) has shown 
in vitro activity against DR-TB (Hugonnet et al., 2009) and there are currently early 
bactericidal activity studies underway to determine its effect on MTB in vivo (Niehaus, 2012). 
CAP, PAS, LIN and M&C are now being used in various combinations with other FLDs and 
SLDs for the management of DR-TB in KZN (Master, 2011). However, standardised DST 
data linked to clinical outcomes are lacking. 
 
In SA, the high prevalence of HIV-1 co-infection compounds the problem of management of 
TB. Patients may already be on antiretroviral (ARV) treatment, or are often commenced on 
ARV treatment together with anti-TB drugs (Abdool Karim et al., 2009; Abdool Karim et al., 









(Burman, 2005). Anti-TB drugs in TB and HIV co-infected patients have to therefore be 
carefully selected. In the era of DR-TB this is not an easy decision as the choices are limited. 
The prescriber has to ensure that all drugs being administered are effective against the strain 
of TB targeted. Whilst empirical treatment was previously an option, this is no longer possible 
given the diversity of drug resistant mutants that are currently circulating in our setting. 
 
It has therefore become mandatory that initial empirical treatment for DR-TB that is 
commenced on diagnosis of cases, be modified as soon as possible by reliable DSTs for 
SLDs. The tailoring of empirical anti-TB drug therapy by DSTs as close to the time of initial 
diagnosis as possible will assist in guiding treatment and prevent the use of drugs that are not 
effective (Kim, 2005) . 
 
Many factors influence the results and the reproducibility of a DST. A major challenge in the 
interpretation of DSTs is that there are no standardised tests for the SLDs used in the 
management of DR-TB in KZN (Shah et al., 2007; Van Ingen et al., 2010). DSTs are also 
influenced by physico-chemical factors in the test environment and are therefore difficult to 
standardise and reproduce (Canetti, et al., 1969; Krüüner, et al., 2003).  
 
Routine DSTs, measure the efficacy of a drug at a given time point. The interaction of the 
drug and microbe over time is not measured. Time kill experiments (TKEs) are the closest 
simulation to measure the latter, and may be used as an indicator of clinical outcome. 
However, the labour intensive nature of these assays does not allow it to be performed 
routinely. A proxy for TKEs is to use DSTs. Ideally, in the absence of clinical outcome data, 
DSTs employed routinely must be interpreted by extrapolating the performance of drugs 
against organisms in TKEs.  
 
The gold standard DST for the FLDs is the agar dilution method (NCCLS, 2003). Liquid 
based assays such as the [(3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide 
(MTT) assay have also been standardised for FLDs and proved to be reliable when tested 
against the gold standard DST (Martin et al., 2005). For INH and RIF DSTs have been 
aligned to the activity of the drugs measured over time by TKEs (Jayaram et al., 2003; 









for phenotypic DSTs for SLDs have not been fully defined. In KZN, SA, DSTs for the more 
recently introduced SLDs and TLDs are not routinely performed. In addition, TKEs for these 
drugs have not been conducted and the DSTs when performed are not interpreted in 
conjunction with the former. We therefore sought to determine the reliability and 
reproducibility of DSTs for SLDs and TLDs in KZN. 
 
The objectives of this study were to therefore: 
1. Validate the reproducibility of the agar dilution DST (gold standard) for SLDs and 
TLDs viz: CAP, PAS, LIN, and M&C. 
2. Validate the reproducibility of a liquid based DST (viz: MTT) for SLDs and TLDs 
viz: CAP, PAS, LIN, M&C. 
3. Compare results obtained using the agar based DST with that of the MTT assay. 
4. Perform TKEs for CAP, PAS, LIN and M&C.  
5. Interpret DST results in conjunction with TKEs. 



















Mycobacterium tuberculosis (MTB) is the causative agent of tuberculosis (TB). This 
organism is spread via the airborne or droplet routes of infection (Knechel, 2009; Mathema et 
al., 2006). It currently ranks second, only to HIV as the most frequent cause of death 
attributable to a single infectious agent (WHO, 2012b). 
 
SA ranks fifth on a list of high TB burden countries, behind India, China, Indonesia and 
Nigeria (Donald et al., 2009). Additionally, HIV infection is highest in these regions (WHO, 
2012b). HIV infection increases the risk of TB reactivation as well as new infections with 
MTB (Getahun et al., 2010). In 2006, it was estimated that 1 in 4 young adults in SA are 
infected with HIV (Dorrington et al., 2006), and 2/3 of them might also be infected with TB. 
  
In the pre-antibiotic era, 65% to 75% of patients’ survived pneumonia caused by 
S.pneumoniae (Bordow et al., 2005).This was due to the ability of the host immune system to 
counteract the infection. The emergence and spread of drug resistant MTB strains places us in 
a situation akin to the pre-antibiotic era. However, a major difference in KZN is the fact that 
the population is largely HIV immune-compromised. KZN is likely to be the province with 
the highest incidence of DR-TB, with 4170 cases of MDR-TB, including 443 XDR-TB, were 
identified in 58 independent sites in KZN between the 1 January 2006 and 30 June 2007 
(Moodley et al., 2011). Studies have shown that the increase in the number of TB cases in 
KZN over the last 25 years, correlates with the exponential increase in HIV infected people in 
this province (Abdool Karim et al., 2009; Naidoo et al, 2007). DR-TB in a largely HIV 
induced immune-compromised population alters the survival odds when compared to the pre-
antibiotic era, when the population at large were immune-competent. 
 
2.1 The causative agent 
Mycobacterium tuberculosis (MTB) is the causative agent of tuberculosis. This organism 









(Rastogi et al., 2001). It is a rod shaped obligate aerobe, and is classified as a Gram positive 
bacterium due to the lack of a classical outer membrane. MTB is between 0.2-0.5µm in width 
and between 2-4µm in length (Knechel, 2009). The family Mycobacteriaceae differs from 
most other bacteria by being acid fast. This refers to the ability of the organism to withstand 
exposure to extreme acidic and alkaline conditions and is not decolorized by acidic solutions 
as applied in the Ziehl-Neelsen (ZN) stain. This acid fast property is attributed to the structure 
of the cell wall. The cell wall has a thick and virtually impermeable outer membrane, which is 
largely due to it being composed of numerous long chains of mycolic and fatty acids 
(Langford et al., 2011). This composition protects the organism and contributes to the 
virulence of the disease by enhancing resistance to various anti-TB drugs (Brennan, 2003). 
Other integral components of the cell wall include lipids and glycolipids, which are uniquely 
arranged and are parallel to the peptidoglycan layer (Knechel, 2009). There are various 
metabolic pathways required for the production of these mycobacterial cell wall lipids and 
these pathways serve as the main targets for the anti-TB drugs. 
 
2.2 Resistance in Mycobacterium tuberculosis 
The control of TB has been declared a national emergency in SA (Abdool Karim et al., 2009). 
DR-TB has been on the rise worldwide, with SA being listed as one of the high burden 
countries. Since 2007, SA has reported increasing numbers of patients with XDR-TB (Olson 
et al., 2011; WHO, 2010).  The management of patients with DR-TB is far from optimal. A 
large proportion of these patients are either not diagnosed, and therefore remain untreated, or 
are diagnosed, but are treated with ineffective drugs or are lost to follow up. Moodley et al 
(2011) revealed that over 65% of the culture confirmed MDR-TB patients in KZN, including 
XDR-TB, were not treated at the MDR-TB referral center. The suboptimal management of 














Resistance can be divided into 3 categories based on the patient’s history of previous TB 
treatment: 
 
a. Primary resistance: a patient is infected with an already resistant strain of MTB and was 
not on any treatment for TB prior to this (Cohn et al., 1997; Mathema et al., 2006; Zhang 
and Yew, 2009). 
 
b. De Novo/Acquired resistance: A patient is on anti-TB treatment, or has had one or more 
previous TB treatment episodes which add up to more than one month. It is perceived that 
the resistant isolate has become resistant due to mutations and had selective advantage due 
to the treatment episodes (Cohn et al., 1997; Mathema et al., 2006; Zhang and Yew, 
2009). 
 
c. Initial resistance: the patient’s history of previous anti-TB treatment is unknown; 
therefore, it may be a combination of primary resistance, and undisclosed acquired 
resistance (Cohn et al., 1997; Zhang and Yew, 2009). 
 
MTB resistance may be classified based on drug susceptibility patterns.  
 
a. Mono-resistant TB: TB caused by MTB resistant to one of the FLDs (Table 1) (WHO, 
2013) 
 
b. Multi-drug resistant TB (MDR-TB): TB caused by MTB resistant to the two most potent 
FLDs viz. INH and RIF (WHO, 2008a; WHO, 2013). 
 
c. Pre-extensively drug resistant TB (pre-XDR-TB): TB caused by an MDR MTB strain with 
additional resistance to either fluoroquinolones or a second line injectable drug (i.e. CAP, 










d. Extensively-drug resistant TB (XDR-TB): TB caused by an MDR MTB strain with 
additional resistance to one of the fluoroquinolones and any of the second line injectable 
drugs (CAP, KAN, AMIK) (WHO, 2008a; WHO, 2013). 
 
e. Totally drug resistant TB (TDR-TB): TB caused by an XDR-TB strain with additional 
resistance to 5 other drugs. TDR-TB strains are therefore resistant to a total of 9 different 
drugs (Migliori et al., 2007; Velayati et al., 2009). 
 
Reported XDR-TB cases have escalated since the outbreak in 2006 (Gandhi et al., 2010; Moll 
et al., 2007; Olson et al., 2011). Pillay and Sturm (2007) reported that this outbreak and many 
of the previous MDR and XDR-TB cases were caused by the F15/LAM4/KZN strain. XDR-
TB has since been documented in more than 60 different clinics and hospital settings in KZN 
(Moodley et al., 2011). It has also been reported in all of SA’s provinces (SAPA, 2007). 
 
Higher morbidity and mortality rates are present in patients with DR-TB, due to the treatment 
options being limited and less successful as opposed to that of the susceptible form of 
infection (Gandhi et al., 2010). These morbidity and mortality rates are even higher when DR-
TB patients are co-infected with HIV (Reid and Shah, 2009). The management of patients 
with DR-TB is often prolonged and complex. This may result in poor patient compliance, 
thereby promoting transmission to others as well as de novo resistance development in the 
individual. 
 
The cost to treat a patient with drug susceptible TB in the United States of America (USA) is 
$ 10, whereas to retreat a patient it costs $ 5000-10000 i.e. the cost of 1 retreatment is 
equivalent to initially treat 500-1000 patients (Caminero, 2005). According to a survey 
conducted by Dr. I.H. Master in 2010, it costs R67 per month for treating a patient for 
standard TB in the intensive phase (first phase of treatment) and R42 per month for the 
continuation phase (second phase of treatment). For MDR-TB treatment in the intensive phase 
and the continuation phase, it costs R1207 and R968 per month respectively. XDR-TB 
treatment in the intensive and continuation phase costs a markedly higher price of R6654 and 









2.3 Factors contributing to drug resistance 
It is generally accepted that acquired bacterial resistance is a man-made problem Lalloo 
(2010), reported on the factors that result in the selection of resistance in MTB in patients on 
anti-TB treatment. These factors include administration of ineffective drugs as well as 
incorrect doses, poor absorption of the drug, drug antagonism, shortages of drugs at hospitals 
and clinics etc. Clinicians further intensify the problem, if they continue treatment with a 
failing regimen, or if only one anti-TB drug is added to the treatment regimen, when treatment 
failure occurs (Lalloo, 2010). 
 
A factor contributing to the spread of DR-TB is delayed diagnosis of TB. Until 2007, culture 
and susceptibility testing was restricted to patients that had interrupted treatment, second 
episodes of TB and treatment failures (SANDOH, 2006; Singh et al., 2007). With the 
emergence of XDR-TB, the policy changed in that now a culture is mandatory in each patient 
suspected of TB (Moodley et al., 2011). All positive cultures for MTB should be subject to 
DST. However, the laboratory capacity to support the new recommendation is insufficient and 
needs to be extended urgently. Another problem that needs to be resolved is the poor 
communication between laboratory staff and clinicians and between clinicians and patients 
resulting in a significant loss to follow up. Poor management practices at clinics and flaws in 
the health system also contribute to resistance development (Lawn et al., 1998; Lienhardt et 
al., 2001; Steen and Mazonder, 1998; Wondimu et al., 2007). This includes poor record 
keeping, lack of directly observed treatment (DOTS), lack of follow up and poor contact 
tracing. This is fuelled by frequent changes of hospital staff, poor education in the 
management of TB patients and poor infection prevention measures (Lalloo, 2010). 
 
2.4 Treatment of Tuberculosis 
Treatment of patients suffering from TB is of medical as well as public health importance. It 
aims at curing the patient, preventing relapses and, in doing so, preventing death from the 
disease (Harries and Maher, 1996). 
 
In SA, TB treatment regimens are based on the WHO recommendations for the management 









as opposed to individualized treatment based on susceptibility patterns. A number of lessons 
have been learnt from the management of drug susceptible infection in the past. These have 
been used to shape the approach to the management of DR-TB (Di Perri and Bonora, 2004) 
and include the following: a single anti-TB agent should not be added to a failing regimen, 
antibiotic mono-therapy should not be considered and at least 3 anti-TB drugs which the 
patient has never taken should be incorporated into the regimen. Overall, the clinician should 
aim to treat the patient with at least 5 anti-TB agents to which the organism is not resistant. 
 
Combined drug therapy is thought to be more effective than mono-therapy since it decreases 
the selection for resistance.  (Rieder, 2002; Schluger et al., 1996) .According to the South 
African National Department of Health (SANDOH) policy guidelines for the treatment of 
DR-TB, patients with MDR-TB and XDR-TB must be on their appropriate regimen of drugs 
for a minimum of 6 months during the intensive phase and at least 18 months during the 
continuation phase. The duration of both of these phases must also be guided by the TB 
culture conversion of each patient (SANDOH, 2011). If severe side effects occur, then 
treatment must be stopped. Treatment must also be stopped, if only one drug can be tolerated 
by the patient, to prevent selection for resistance. It is permissible for one anti-TB drug to be 
exchanged for another because of side effects, not because of treatment failure (SANDOH, 
2011). If, however alternative treatment is not available, then the number of drugs can be 
reduced as long as a minimum of three drugs with proven in vitro activity remain. Culture 
results and DST results must be assessed prior to this change. 
 
There is currently no established regimen for the treatment of XDR-TB. There is also no 
guarantee of a cure, as the MTB isolate infecting the patients may be resistant to the anti- TB 
drugs that are being used for treatment (Banerjee et al., 2008).  
 
In the era of DR-TB, effective management has to be based on reliable DSTs as opposed to 
guidelines. The diversity of susceptibility profiles currently seen amongst TB cases in SA 










2.5 Anti-Tuberculosis Agents 
Novel anti-TB drugs are still a while away from field testing.  In the interim, scientists and 
policy makers are exploring the possibility of using antibacterial agents not traditionally used 
for TB treatment as possible anti-tuberculosis agents. The exact positioning of these drugs in 
the TB treatment algorithms has not been fully elucidated, but may form part of the second or 
third line treatment regimen (Banerjee et al., 2008). The classes of drugs were referred to as 
first line drugs (FLD), second line drugs (SLD) and third line drugs (TLD) (table 1) (Banerjee 
et al., 2008). However, due to increasing resistance, this classification is no longer applicable 
since SLDs and TLDs are used interchangeably.WHO has recently released a new 















Table 1: Classes of Anti -TB Drugs 
   First Line Drugs Second Line Drugs Third Line Drugs  
   Isoniazid Fluoroquinolones Linezolid 
Rifampicin Injectables: Clarithromycin 
Streptomycin Amikacin and Kanamycin Imipenem 
Pyrazinamide Capreomycin Amoxacillin and Clavulanate 
Ethambutol Ethionamide Clofazimine 
 













Table 2: World Health Oganisation grouping of Anti-TB Drugs  
Group Drugs 














Group 4: Oral bacteriostatic  Ethionamide 
second line drugs Prothionamide 
 Cycloserine 
 Terizidone 
 Para-amino salicylic acid 
  
Group 5: Drugs of unclear efficacy Clofazamine 
(Not recommended for use in  Amoxicillin/Clavulanate 
















2.5.1 First line drugs (FLDs) 
Streptomycin (SM) 
In 1944 SM was discovered by Selman Waksman and was the first record of a drug effective 
against TB (Schatz and Waksman, 1944). It binds to the 30S ribosomal unit, and interferes 
with the decoding of aminoacyltRNA and thus inhibits mRNA translation, or causes 
insufficient translation (Da Silva and Palomino, 2011). By interfering with ribosomal 
function, it prevents protein and polypeptide synthesis (Kolyva and Karakousis, 2012). SM 
shows strong bacteriostatic activity against TB (Schatz and Waksman, 1944) and bactericidal 
activity against bacilli in the exponential phase (Di Peri and Bonora, 2004). However a few 
months after being introduced in the treatment of tuberculosis meningitis in children, relapse 
was seen and was attributed to the development of resistance to SM (Kolyva and Karakousis, 
2012). This provided initial evidence that mono-therapy for the treatment of MTB rapidly led 
to resistance development. Patients have poor oral absorption of SM (Kolyva and Karakousis; 
2012). It therefore needs to be administered as an intra-muscular injection, which has been 
described as very painful (Gundersen and Bietti 1949). There is also several safety concerns 
associated with treatment using SM. One of the most severe is the development of ototoxicity 
with resultant deafness. 
 
Isoniazid (INH) 
INH was first synthesized in 1912 in Prague (Meyer and Mally, 1912). It was only in the early 
1950’s that it was discovered to be effective against TB (McDermott, 1969; Robitzek and 
Selikoff, 1952). INH is a small water soluble molecule, which is a hydrazide of isonicotinic 
acid. It is able to enter the host cells easily (Mackaness and Smith, 1952), and is then able to 
pass through the MTB membrane (Bardou et al., 1998). The active form of INH inhibits 
synthesis of phospholipids (Brennan, et al., 1970; Kolykova and Karakousis, 2012) and 
nucleic acid (Gangadharam et al., 1963). It was also shown to prevent the metabolism of 
nicotinamide adenine dinucleotide (NAD) (Bekierkunst, 1966). The main mode of action of 
INH against MTB is the inhibition of the mycolic acid synthesis and elongation of fatty acids 
of MTB (Quémard et al., 1995). This is achieved by supressing the activity of the InhA 
enzyme (Dessen et al., 1995; Rozwarski et al., 1998; Zhang and Guo, 2012).  INH displayed 









dividing bacteria both intracellularly and extracellularly (Di Perri and Bonora, 2004; Snell, 
1998). Due to its early bactericidal activity it has an increased capacity to render patients non-
infectious more rapidly than some of the other anti-TB agents (Di Perri and Bonora, 2004). 
 
Pyrazinamide (PZA) 
PZA was first discovered as an anti-TB agent in 1954 (Zhang and Mitchison, 2003).This 
compound is an analogue of nicotinamide, which is a Vitamin B3 precursor that has 
bactericidal activity against MTB (Di Perri and Bonora, 2004). It is thought to act as a 
sterilizing drug, and kills bacteria within an acidic environment i.e. a pH of 5.5 (McDermott 
and Tompsett, 1954; Mitchison, 1985). It also plays a unique role in that it is able to shorten 
the duration of therapy (Steele and Des Preze, 1988; Zhang and Mitchison, 2003), from 9-12 
months, to a period of 6 month in combination therapy with INH and RIF (Iseman, 2002). 
This is due to its ability to successfully eradicate bacilli that are in a semi-dormant state 
within acidic environments during active inflammation whilst all other anti-TB drugs are 
unable to do this (Heifets and Lindholm-Levy, 1992). PZA given in the 2 months of intensive 
therapy is thought to rapidly reduce bacterial load and the 4 months of maintenance therapy 
will then eradicate the remaining organisms (Heifets and Lindholm-Levy, 1992). It was also 
shown to have a strong synergistic relationship with R (Grosset, 1978). PZA has no or very 
little effect on other mycobacteria, including M. bovis (Fuursted et al., 1993; Zhang and 
Mitchison, 2003). It is believed that this is due to the lack of the enzyme pyrazinamidase 
(Pzase) in M. bovis (Zhang and Mitchison, 2003). This enzyme is involved in the drugs 
activity against MTB, as it hydrolyses the PZA to pyrazinoic acid (Scorpio and Zhang, 1996), 
which is the active form of PZA (Zhang et al., 2003). Pyrazinoic acid has been reported to 
interfere with the energetics and proton motive force of the membrane as well as the 















EMB was discovered in 1961 (Thomas et al., 1961). It is commonly referred to as a 
“companion drug” since it is frequently used in combination with other drugs for the 
treatment of TB (WHO, 2006b). Although it was not very effective in killing bacteria, it 
prevented resistance when used in combination with other drugs (Hoek et al., 2009) and 
displays bacteriostatic activity (Di Perri and Bonora, 2004). Its mode of action is linked to the 
inhibition of 3 arabinosyltransferase enzymes (EmbA, EmbB and EmbC) (Goude et al., 2009). 
The first two are involved in converting arabinose into arabinan, and lastly arabinogalactan. 
This is an important constituent of the MTB cell wall (Goude et al., 2009). EmbC facilitates 
the formation and production of lipoarabinomannan (LAM), which is a cell wall glycolipid 
(Goude et al, 2009). EMB inhibits many cellular pathways. It inhibits ribonucleic acid (RNA) 
metabolism (Forbes et al., 1962; Forbes et al., 1965) and in turn prevents MTB growth 
(Zhang and Guo, 2012). EMB was shown to prevent phospholipid synthesis (Cheema and 
Khuller, 1985a; Cheema and Khuller, 1985b) and to inhibit the transfer of mycolic acids into 
the cell wall (Takayama et al., 1979). 
 
Rifampicin (RIF) 
RIF was discovered in the early 1960’s and this, in combination with PZA and INH, allowed 
for a reduction in treatment duration, from 18-24 months to 6 months (Kabra and Srivastava, 
2011).It is described as a potent ‘sterilising’ drug and its added benefit in combination with 
INH is the ability to kill very slow dividing and non-replicating bacilli (Blumberg et al., 2003; 
Jindani et al., 1980; Rieder et al., 2002). It also kills persistent bacilli, throughout the duration 
of TB treatment (Grosset et al., 1998; Mitchison, 1985). To date, INH and RIF are the most 
effective antimycobacterial agents known to rapidly decrease the bacterial load caused by 
susceptible strains (Harries and Maher, 1996, WHO, 2008a). RIF is able to pass through the 
MTB membrane, as it is lipophilic in nature (Wade and Zhang, 2004). Its mode of action 
involves inhibiting transcription. This occurs when it binds to the bacterial dependent enzyme, 
RNA polymerase, and inhibits activity of the β subunit of this enzyme. This unit is 










2.5.2 Second line drugs (SLDs) 
The treatment of DR-TB involves using toxic drugs that are less potent than FLDs. These 
have to be used for a longer duration.  In SA, there are numerous anti-TB drugs that are used 
for treating MDR-TB and XDR-TB. Not all of these drugs have been placed into set treatment 
regimens. Table 2 categorizes SLDs into 5 different classes, based on their efficacy and 
experience of use. Some of these drugs present in the SLD category are placed in the TLD 
category of other treatment regimens (SANDOH, 2011; WHO, 2008b) 
 
Cycloserine 
Cycloserine is recommended by the WHO as a SLD for the treatment of MDR-TB (Hwang et 
al., 2013). It is useful as an additional drug to the MDR-TB treatment regime, as it may 
prevent the development of drug resistance, since it has not shown cross resistance with other 
active TB drugs (SANDOH, 2011; Wolinsky, 1993). Cycloserine displays bacteriostatic 
activity with MTB, however due to its many toxic effects at its effective dose, it is seldom 
included in national treatment programmes (David, 2001; Hwang et al., 2013). Its mode of 
action involves inhibiting peptidoglycan synthesis (Kolyva and Karakousis, 2012). 
 
Ethionamide (ETH) 
ETH belongs to a group of drugs called thioamides (Di Perri and Bonora, 2004). Its mode of 
action is similar to that of INH, in preventing the synthesis of mycolic acids which are found 
on the cell wall of MTB (Di Perri and Bonora, 2004; Quemard et al., 1992). It does this via 
inhibition of the inhA gene product enoyl-ACP reductase (Johnsson et al., 1995), when it 
binds to the reductase InhA enzyme (Kolyva and Karakousis, 2012). It exhibits bactericidal 
activity in vitro (Steenken and Montabine, 1960). Side effects of ETH are dose related, and it 
is thought to be responsible for causing nausea, vomiting, dizziness, fatigue and depression. It 
has also been reported to cause gastro-intestinal disturbances, hepatotoxicity and 
hyperthyroidism (Banerjee et al, 2008; Di Perri and Bonora, 2004). Patients generally have 












Amikacin (AMIK) and kanamycin (KAN) belong to the aminoglycoside family. They have 
very strong concentration dependent bactericidal properties (Freeman et al., 1997; Gilbert, 
2000). Their bactericidal activity is only effective against rapidly dividing mycobacteria 
(Heifets and Lindholm-Levy, 1989). They are thus not effective when bacilli are not 
replicating, which may be for long periods, during the stationary phase of growth (Heifets and 
Lindholm-Levy, 1989; Jana and Deb, 2006). Aminoglycosides have to penetrate the 
mycobacterium, in order for them to reach their molecular target (Jana and Deb, 2006). They 
are responsible for preventing protein synthesis in MTB, by binding to the 30S subunit 
proteins (Kotra et al., 2000) and 4 nucleotides of the 16S rRNA and a single amino acid of the 
S12 protein. This action interferes with the decoding of site 1400 in the 16S rRNA of the 30S 
subunit (Jana and Deb, 2006; Melancon et al., 1992). This results in the incorrect amino acid 
being inserted into the polypeptide (Heifets and Lindholm-levy, 1989; Perri and Bonora, 
2004). Thus these polypeptides are non-functional. When the aminoglycosides bind to the 
ribosomal unit this makes these molecular targets unavailable for translation resulting in cell 
death (Kotra et al., 2000). The mode of action of AMIK and KAN are thought to be similar, 
but it is thought that their binding sites on the molecular targets are different. The prolonged 
use of aminoglycosides leads to toxicity related nephrotoxicity and ototoxicity (Peloquin et 
al., 2004). The side effects of these agents are duration and dose related (Smith et al., 1986). 
It is thought that AMIK is generally active against SM resistant strains of MTB (Hoffner and 
Kallenius, 1988; Perri and Bonora, 2004). However, AMIK resistant strains are generally 
resistant to SM. Cross resistance with KAN is well described (McClatchy et al., 1977). 
 
Fluoroquinolones 
Ofloxacin , ciprofloxacin, sparfloxacin, levofloxacin, gatifloxacin and moxifloxacin all belong 
to the fluoroquinolone class of drugs (Perri and Bonora, 2004).Ofloxacin and ciprofloxacin 
have both been approved as SLDs for the treatment of MDR-TB, by the WHO, Centers for 
Disease Control and Prevention (CDC) and the American Thoracic Society (Blumberg et al., 
2003 ; Crofton et al., 1997). The safety and tolerability of gatifloxacin and moxifloxacin, is 
still being investigated, as they are both fairly new fluoroquinolones. They have been 









It is believed that all fluoroquinolones have similar modes of action. They are capable of 
penetrating macrophages and are responsible for bactericidal activity (Auwera et al., 1988; 
Rastogi et al., 1996). Fluoroquinolones interfere with DNA (deoxyribonucleic acid) gyrase, 
and prevents DNA replication and transcription (Kolyva and Karakousis, 2012; Zhang and 
Guo, 2012). It affects the function of this enzyme, which is to prevent excessive supercoiling 
of the DNA during replication or transcription. Thus flouoroquinolones prevent the correct 
number of unwinding to occur for 1 DNA helix to divide into two. They are thereby able to 
block off bacterial DNA replication and inhibit normal cell division (Drlica et al., 1996). 
 
Capreomycin (CAP) 
CAP is a complex cyclic polypeptide isolated from Streptomyces capreolus (Donomae, 1966). 
It is bacteriostatic and its mode of action involves binding to the 16S rRNA ribosomal subunit 
and altering its structures (Wade and Zhang, 2004), thus inhibiting the translocation reaction. 
It is responsible for the inhibition of protein synthesis through interaction with ribosomes 
(Maus et al., 2005a). It displays strong activity on persistent non-replicating forms of MTB 
(Filippini et al., 2010; Heifets et al., 2005). CAP cannot be administered orally, but rather 
intramuscularly, or intravenously. It is a fairly expensive anti-TB drug with numerous side 
effects. Some of the most serious side effects include nephrotoxicity, ototoxicity, electrolyte 
imbalances, anaemia, leukopenia, hypersensitivity, and hypokalaemia (Donomae, 1966; 
Garfield et al., 1966; Obrien, 1993). Over the past few years, there has been an increase in 
DST research on CAP. CAP has been tested on both solid and liquid based DST methods in 
an effort to determine a critical concentration, breakpoint concentrations or minimum 
inhibitory concentration (MIC) for MTB. In 2003 a study compared the proportion method to 
the colorimetric resazurin microtitre assay (REMA) (Martin et al., 2003). This study used 150 
susceptible and MDR-TB clinical isoaltes. These isolates were collected from Bolivia, Peru 
and other eastern European countries. The proposed breakpoint value for CAP was 10µg/ml 
when using the proportion method and 2.5µg/ml when using REMA (Martin et al., 2003). In 
2010 a comparative study by Van Ingen et al, compared the agar dilution method to the MGIT 
960 system using 28 MDR and XDR-TB isolates (Van Ingen et al., 2010). These two DST 
methods revealed MICs that were fully concordant.The breakpoint concentrations were the 









a study by Kam et al, in 2010. This study made use of the absolute concentration method, the 
1% proportion method and the radiometric BACTEC 460 method. The breakpoint 
concentrations were 1.5-2 mg/l in the BACTEC method, 8mg/l in the 7H10 agar method and 
40mg/l in the Lowenstein Jensen medium (LJs) used for the absolute concentration method 
(Kam et al., 2010). This still follows the trend that values are higher in the solid media DST 
methods.  
 
Para-amino salicylic acid (PAS) 
PAS was discovered to have anti-TB activity in 1943 by Lehmann (Lehmann, 1946). It is 
classified as bacteriostatic and prevents conversion of para–amino benzoic acid into folic acid, 
and in so doing, it prevents the biosynthesis of folic acid (Peloquin et al., 1999). Bacteria are 
often unable to use external sources of folic acid, thus PAS prevents access to folic acid which 
is required by the bacterium for cell growth and multiplication. PAS also interferes with the 
uptake of iron by bacteria (Wade and Zhang, 2004). It is administered orally, and the current 
granular formulation of PAS, is more tolerable, and less toxic than the previous tablet 
formulation (Akhtar et al., 1968).  Side effects include hypersensitivity reactions, 
hypothyroidism, thrombocytopenia, jaundice, lymphadenopathy, leucocytosis, malabsorption, 
nausea and other gastrointestinal problems (Akhtar et al., 1968). It also affects the uptake of 
vitamin B12, and thus a supplement of this should be given to patients on PAS treatment 
(Paaby and Norvin, 1966). Research on DST methods using PAS on MTB isolates aims to 
determine the MIC, breakpoint and critical concentrations. This will aid in determining 
concentrations of PAS for treatment regimens. The study by Kam et al, in 2010 (mentioned 
above) proposed that the critical concentrations for PAS in LJs are 1mg/l and in 7H10 agar 
and the BACTEC 460 system is 0.5-1mg/l. According to Martin et al, (2003) the critical 
concentration for PAS when using LJs or 7H11 medium, is 0.5µg/ml and when using the 
liquid 7H9 broth in the REMA method it is 2µg/ml. 
 











2.5.3 Third Line Drugs (TLDs) 
Linezolid (LIN)  
LIN is the first oxazolidinone that was developed and approved for clinical use (Bozdogan 
and Appelbaum, 2004). It exhibits good antimycobacterial activity (Cynamon et al., 1999) as 
well as good antimicrobial activity against a wide variety of Gram positive pathogens 
(Stevens et al., 2004). LIN inhibits synthesis of bacterial ribosomal proteins (Shinabarger, 
1999). This agent is able to bind on the 50S ribosomal subunit close to the 30S unit, and 
thereby prevents the formation of a 70S initiation complex (Rodriguez Diaz et al., 2003). This 
mode of action is unique, and is believed to preclude cross resistance to other available anti-
TB drugs. LIN possesses a unique structure that is completely synthetic, and therefore there is 
no pre-existing resistance (Moellering, 2003). It displays excellent activity on MTB cultures 
in both the logarithmic and stationary phase of growth. This is a characteristic that has only 
been demonstrated with INH and RIF. Recent studies have shown that LIN is effective in the 
treatment of MDR-TB (Huang et al., 2008), however it must always be used in combination 
with other SLDs and TLDs. Several studies also show synergistic activity between LIN and 
fluoroquinolones which has been proven to enhance linezolid’s effect in the latent phase of 
infection (Rodriguez Diaz et al., 2003). LIN also has synergistic activity with RIF and can 
therefore be used to treat patients infected with MTB strains that are resistant to INH but not 
to RIF (Rodriguez Diaz et al., 2003). Treatment with LIN over long durations is associated 
with many side effects e.g. neurological toxicity like peripheral neuropathy as well as 
pancreatitis and anaemia (Fortún et al., 2005). LIN was tested against MDR and XDR-TB 
clinical isolates and MTB complex strains using the agar dilution and automated MGIT 
method (Van Ingen et al., 2010). This was done in an effort to determine the MIC of LIN 
against MTB isolates of varying susceptibility profiles. This will aid in determining the best 
concentrations at which LIN is most efficient against MTB. The DST results revealed a 
breakpoint concentration of 1 µg/ml for LIN when using both these methods. This breakpoint 
concentration was also shown by Alcalá et al in 2003 when using the agar proportion method. 
A study in 2007 by Richter et al was the first to report a LIN resistant clinical isolate, which 










Meropenem combined with Clavulanic Acid (M&C) 
Meropenem is a ß- lactam drug, which belongs to the class of carbapenems. These have no 
effect on MTB as it is inactivated by the enzyme ß –lactamase produced by the bacteria (Cole 
et al., 1998). When meropenem was combined with a ß-lactamase inhibitor, such as 
clavulanic acid, it was shown to inhibit the growth of XDR-TB (Hugonnet et al., 2009). A 
similar bactericidal activity was also displayed when amoxicillin and clavulanic acid were 
combined and administered to TB patients in 1998 (Chambers et al., 1998). Strong inhibitory 
activity of this combination was also shown on anaerobically grown MTB cultures (Hugonnet 
et al., 2009). M&C was also active against the growth of rapidly multiplying bacteria as well 
as persistent bacteria (Hugonnet et al., 2009). This in vitro study which tested 13 XDR-TB 
isolates revealed that most M&C MIC values for these isolates were less than 1µg/ml. These 
MIC values were also similar to that of the susceptible strain (H37Rv) that was tested. These 
two anti- TB drugs are both food and drug administration (FDA) approved and are non-toxic, 
with very few side effects, thus rendering them appropriate for TB treatment in adults and 
children. Clavulanic acid is also the only FDA approved ß-lactamase inhibitor that 
irreversibly inhibits blaC (Hugonnet et al., 2009). 
 
2.6. Resistance mechanisms 
Bacterial resistance to anti-TB agents can be due to drug inactivation, alteration of the 
structure of the drugs target, a decrease in the quantity of the drug within the host or bacterial 
cell, which can be caused by either decrease in permeability, and/or an increase in activity of 
efflux pumps (Li and Nikaido, 2004). Resistance can also occur when the pro-drug is not 
converted to its active form. This is necessary for INH, ETH and PZA (Kolyva and 
Karakousis, 2012; Raynaud et al., 1999; Scior et al., 2002). There are also various forms of 
bacterial resistance. Intrinsic resistance refers to resistance that is due to a natural feature of 
the organism. In MTB, an example of intrinsic resistance would be its use of the low 
permeable cell wall that it possesses (De Rossi et al., 2006). This wall is made up of layers of 
lipids and glycolipids that are arranged in a unique manner, which helps control the type of 
molecules that enter the cell. It can thus prevent the entry of various drug molecules (Brennan 
2003; Niederweis, 2003). Acquired resistance occurs when an exogenous resistant gene is 









Normark, 2002). MTB has a unique ability to remain in a latent state within a host who shows 
no signs or symptoms of possessing the MTB strain. It can then convert to its active form, 
which is then infectious (Stewart et al., 2003; Zhang, 2004). Resistance of MTB to various 
anti-TB agents is often a result of mutations in chromosomal genes. The sites and positions of 
these mutations vary in each gene, but are specific for the various anti-TB agents. These 
mutations are often found on the gene that is the drug target, or that controls the activation of 
the actual anti-TB agent (Wade and Zhang, 2004; Zhang and Telenti, 2000). Another 
mechanism of resistance that MTB makes use of are efflux pump systems (Levy, 2002; 
Nikaido, 1994).This system controls the entry of various drug molecules, and is also able to 
pump out drug molecules from within the cell, thus protecting MTB from the mode of action 
of the anti-TB agent, and ensuring its survival (Lomovskaya and Watkins, 2001). Efflux 
pump systems exhibit specificity, and thus can mediate the transport of specific molecules 
into and out of the cell (Neyfakh, 2002).  
 
Table 3 shown below (Banerjee et al., 2008) summarizes the specific genes that develop 
























Table 3 : Anti -TB drugs and  Drug Resistance conferring Gene 
Mutations 
  
Anti-TB drug Mutated genes conferring resistance 
  
First Line Drugs  






Second Line Drugs  
Fluoroquinolones gyrA, gyrB 
Injectables:  
Amikacin and Kanamycin rrs 
Capreomycin rrs, tlyA 
Ethionamide inhA, etaA/ethA 
Para-aminosalicylic acid  thyA 
Cycloserine alrA , ddl (shown only in M.smegmatis) 
  
Third Line Drugs  
Linezolid rrl1 and rrl2 
Clarithromycin - 
Imipenem - 











2.6.1 Resistance mechanisms of the drugs used in this study 
Resistance to INH 
Resistance to INH can be due to mutations in many genes. These include ndh, kasA, inhA, 
oxyR, furA, ahpC (Banerjee et al., 2008; Riska et al., 2004). Mutations in the katG gene are 
most common, and account for over 50 % of resistant cases (Banerjee et al., 2008; Riska et 
al., 2004). Mutations in the katG gene interfere with the function of the catalase-peroxidase, 
which is to activate the INH pro-drug (Kolyva and Karakousis, 2012). Mutations at this gene 
can result in insertions, deletions, missense, nonsense mutations and even entire gene 
deletions, although the latter is uncommon (Kolyva and Karakousis, 2012). Single point 
mutations also occur in the katG gene, which results in a substitution of threonine for serine at 
the 315 site. This is the most common mutation that accounts for resistance to INH (Abate et 
al., 2001; Marttila et al., 1998).This mutation results in a decrease in the activity of catalase 
and peroxidase (Rousse et al., 1996; Saint-Joanis et al., 1999). Low level resistance to INH 
was also revealed when mutations were present in the inhA gene. This was also evident at the 
promoter region of the operon (mabA inhA) (Musser et al., 1996). Mutations in the inhA gene, 
decreases the affinity of the enzyme to nicotinamide adenine dinucleotide dehydrogenase 
(NADH), which it is dependent on (Basso et al., 1998). Mutations at the promoter region of 
the operon results in over expression of the wild-type enzyme. Mutations were present in the 
ndh gene, in INH resistant MTB isolates. These isolates did not have mutations in the katG 
and inhA genes (Lee et al., 2001). The ndh gene is responsible for encoding NADH 
dehydrogenase, therefore mutations at this site, affects the peroxidation of INH (Miesel et al., 
1998). 
 
Resistance to INH was also found in isolates that lack mutations in all of the above mentioned 
genes. This forms a quarter of the INH resistant isolates (Karakousis, 2009), thus implying 
that there are alternative mechanisms of resistance to INH. The efflux pump system was 
suggested to be one of these alternate mechanisms. A study by de Steenwinkel et al (2010) 
showed that when reserpine, which is the efflux pump inhibitor, was added to the INH 











Resistance to CAP 
Resistance to CAP is caused by mutations in the rrs gene (Jugheli et al., 2009; Maus et al., 
2005b) and tlyA gene (Kashuba et al., 1999; Maus et al., 2005a). Mutations that occur in the 
rrs gene encoding for the 16S rRNA is responsible for resistance to CAP and AMIK 
(Alangaden et al., 1998; Taniguchi et al., 1997). Resistance to CAP and viomycin is due to 
mutations in the tlyA gene, which encodes for 2’-o-methyltransferase of the 16S rRNA and 
the 23S r RNA (Johansen et al., 2006) and is responsible for the addition of methyl groups to 
the rRNA (Sander et al., 1996). Cross resistance between KAN and AMIK is common but not 
with SM (Jureen et al., 2010). Cross resistance has been reported between CAP and viomycin, 
however there is very little information available on this mechanism (Mclatchy et al., 1977). 
 
Resistance to PAS 
The mechanisms of resistance to PAS are still unclear. It is thoughout to be associated with 
mutations in the thyA gene (Rengarajan et al., 2004) and in Thr202Ala region (Kolyva and 
Karakousis, 2012). Mutations at the thy A gene, codes for the enzyme thymidylate synthase A 
(Rengarajan et al., 2004). This enzyme is associated with the biosynthesis of thymine in the 
folate pathway, and it is also the enzyme which is responsible for activating PAS. PAS is a 
pro-drug, similar to INH, PZA and ETH, and it thus requires a fully functional activating 
enzyme, to ensure that it is converted to its active state (Rengarajan et al., 2004). A mutation 
at the thyA gene, will therefore interfere with thymidylate synthaseA ability to activate PAS, 
this will in turn prevent PAS from its mode of action against the MTB isolates. 
 
Mutations at these sites however are not present in all PAS resistant MTB strains (Mathys et 
al., 2009) and are even present in some PAS susceptible MTB strains (Leung et al., 2010) 
thus implying that there are additional mechanisms of resistance to PAS, that need to be 
investigated. Mathys et al (2009) attempted searching for mutations in 8 other genes, to 
determine if this could be associated with resistance to PAS. These 8 genes included 5 other 
enzymes involved in the folate pathway and thymine biosynthesis as well as in 3 N-acetyl 
transferase genes. However no mutations were found in any of these sites. Additional work is 










Resistance to LIN 
The synthetic nature of LIN proves to be advantageous, since no prior mechanisms of 
resistance are evident among gram positive bacteria (Moellering, 2003). However, resistance 
has recently been reported. To identify these mechanisms of resistance, various genes have 
been analysed and sequenced. These include the gene that codes for the 23S rRNA 
methyltransferase (Richter et al., 2007), which is the erm37 gene. Other genes that have been 
investigated include the entire 23S rRNA gene and the rplV and the rplD genes. The two latter 
genes code for the L4 and L22 ribosomal proteins respectively. Sequences however revealed 
that there were no differences between susceptible and resistant strains or between these genes 
in the wild type H37Rv strain and the resistant isolates (Richter et al., 2007). Isolates 
displaying high level resistance to LIN , where MICs were between 16-32mg/L revealed 
mutations at the G2061T and G2576T region of the 23S rRNA (Hilleman et al., 2008). These 
mutations however, were not present in the isolates that showed low level resistance to LIN 
(with MICs of 4-8mg/L). Efflux pumps as a possible mechanism of resistance was also 
investigated (Richter et al., 2007). Other mechanisms of resistance that require further 
research, is the role of the ribosomes of the LIN resistant MTB strains, as well as the rate at 
which the drug is being imported into the MTB (Richter et al., 2007). 
 
Resistance to M&C: 
All ß-lactams, meropenem inhibits penicillin binding proteins (PBPs) and therefore prevents 
the production of peptidoglycan. MTB prevents that by producing a ß-lactamase coded for by 
the blaC gene. Mutations in the PBP coding region of the genome lead to alterations in the 
drug target (Lister et al., 2009). Mutations in the blaC gene result in inactivation of the β-
lactamase enzyme (Lister et al., 2009). Such mechanisms of resistance also exist in other 
bacterial species (Lister et al., 2009). 
 
2.7 Drug Susceptibility Tests (DSTs) 
2.7.1 Importance of DSTs 
A vital factor in TB control is the development of a DST that is rapid, reliable and affordable. 









prevent the spread of TB, as well as the spread of resistance strains. DSTs can be used as tools 
to evaluate treatment regimens that are currently being used, and develop means to cope with 
the emergence of drug resistance. It is able to offer insight to various concentrations and 
combinations of anti-TB drugs that may be successful yet are not being administered to 
patients. These tests however are difficult to develop due to the slow growth of MTB, the 
dangers of working with such an infectious organism, the presence of many non-tuberculosis 
strains that are present in the patients’ samples, which often give false positives and the poor 
laboratory infrastructure that is evident in countries with high rates of TB. 
 
DSTs must be evaluated for routine use, against not only test isolates but also clinical isolates 
to determine if there is a difference in sensitivity and specificity of results. This should be 
done, to ensure that the in vitro results obtained can also be successfully compared to patients’ 
clinical outcome. The relationship between DST results and how they can be used to guide 
treatment options can be optimised by ensuring that laboratory staff interpret results correctly, 
and that these reliable results are then sent to clinicians on time (Lobue et al., 2009). Although 
laboratory staff may be trained sufficiently to read results, great care should also be taken to 
ensure that they are trained appropriately to conduct the DSTs correctly. This is due to the 
sensitive nature of DSTs. They are easily affected by numerous external and internal factors. 
Great measures must be taken to ensure that conditions are appropriate for the different tests 
and kept constant during the duration of the DST. These factors include, the type of growth 
medium that is used, the pH of this medium, the temperature at which incubation occurs, the 
type of solvent that the anti-TB drug is dissolved in, as well as errors that must be taken into 
account for such as loss of drug that may occur during filter sterilization, the inoculum of the 
TB culture must be standardised for all DSTs and care must be taken to ensure that dilutions 
of the culture or the anti-TB drugs are carried out correctly and carefully (Kim, 2005). By 
training laboratory staff appropriately, these factors can be controlled and thus results read 
from DSTs have a greater chance of being reliable and reproducible.  
 
A major concern is that DSTs are not conducted routinely. Instead they are only conducted 
when a case seems suspicious or if there is treatment failure. This was evident in countries 
where resources were limited and which also lacked laboratory infrastructure, staff and 









understudy conducted routine DSTs on suspected cases of TB (WHO, 2010). Additionally, a 
study in 2008 revealed that a common problem that was present in many countries, was the 
lack of DSTs being conducted on new cases of TB (Young et al., 2008). In the countries that 
were investigated in this study, less than 5 % of new TB cases had access to DSTs (Young et 
al., 2008). The lack of DSTs being conducted has more serious implications. This is largely 
due to the fact that standard treatment regimens are based on data that is obtained from 
population-level-drug resistance, because of the ever changing epidemiology of DR-TB. Gaps 
in data collection imply that the standard treatment regimens may be inaccurate (Shah et al., 
2011). 
 
In SA, DSTs on various SLD are not being conducted routinely e.g. oflaoxacin and 
kanamycin. This means that patients are still being administered these two drugs, despite a 
lack of resistance data for them (Shah et al., 2011).The study by Shah et al, (2011), showed 
that 68% of the patients at the Tugela Ferry hospital in KZN had XDR-TB, which showed 
patterns of being resistant to 8 drugs i.e. INH, RIF, EMB, SM, Ofloxacin, KAN, CAP, and 
ETH. These patients however, had been receiving treatment of which they were resistant to. 
This in turn increases and spreads resistance as well as increases the risk for treatment failure 
(Shah et al., 2011). DSTs for SLD are therefore critical, in determining a patient’s 
susceptibility profile, and ensuring that the correct treatment is administered, this will aid in 
preventing patients from being subjected to anti -TB drugs that they are already resistant to.  
 
When MDR-TB patients are treated properly it can result in at least half of the TB patients 
converting to a negative sputum culture, within 3 months and with improved outcomes 
(Telzak et al., 1995). DSTs for SLDs are not standardized throughout the world and do not 
have good reproducibility, even among national reference laboratories (Kim et al., 2004). 
Despite numerous published recommendations (WHO, 2001), and validation of DSTs on 
SLDs in various studies (Krüüner et al., 2006 ; Rüsch-Gerdes et al., 2006; Sanders et al.,  
2004) there are still many variations of the critical concentrations of these SLDs, during DSTs 
in the different laboratories (Kim et al., 2004; Pfyffer et al., 1999). Another problem faced 
when performing DSTs on SLDs is the lack of quality control (Fattorini et al., 2008; Laszlo et 
al., 2002). Further research is required to determine in vitro efficacy of results obtained during 









results of drugs and the actual effect of the anti-TB agents on patients i.e. the clinical outcome 
(Banerjee et al., 2008 ;Krüüner et al., 2006; WHO , 2001).  
 
Discrepancies were evident when comparing DST results using two different methods i.e. a 
solid medium based DST and a liquid medium based DST for cycloserine, ETH, CAP, and to 
a lesser extent, clofazimine and rifabutin (Pfyffer et al., 1999). These differences could be due 
to a variety of possibilities i.e. due to the two different DST methods, due to the isolate/ strain 
that is tested containing a mixed population or due to the isolate/strain being border line 
resistant to the drug tested. 
 
It is presumed that DSTs on TLDs will experience the same problems as SLD. In order for a 
DST to be successful, it must be optimised for a control TB isolate (H37Rv). The procedure 
must be properly standardised and be simple so as to avoid errors, and obtain reproducible 
results. A DST for MTB can be determined by either observing growth of the TB isolate in 
the presence of antimicrobials, or by observing the metabolic inhibition of it. It can be 
detected by macroscopic observation of the growth in drug free controls (DFC) and drug 
containing wells. It can also be detected by measuring the metabolic activity or products, by 
lysis with mycobacteriophages, and lastly it can be done using molecular based techniques to 
identifying genetic mutations which confer drug resistance (Kim, 2005). 
 
2.8 Types of DSTs 
2.8.1 Phenotypic methods 
DSTs on solid media are accepted as the gold standard for phenotypic DSTs of FLDs (Canetti 
et al., 1963; Canetti et al., 1969; NCCLS, 2003; Piersimoni et al., 2008). This is largely due 
to it being easily standardised on solid media, as well as it is more reproducible, as it is a less 
sensitive method than a liquid based DST. The use of LJs and Middlebrook media has been 
standardized for FLDs, yet are still unreliable and not reproducible for SLDs and TLDs (Shah 












This DST has been well established on solid media such as Middlebrook 7H10 agar or LJs 
(CLSI, 2007; Kent et al., 1985; Kim, 2005). It involves incorporating a known concentration 
of the drug, mainly the breakpoint concentration, into the media and thereafter inoculating the 
decontaminated clinical sample (Siddiqi et al., 2012). An advantage of this method over the 
indirect DST method is that it provides results faster and it offers a representation the patient’s 
original bacterial population (Ramachandran and Parmasivan, 2003). The microscopic 
observation drug susceptibility assay (MODS) and the nitrate reductase assay (NRA) are 
examples of non-commercial direct DSTs. 
 
Indirect DST 
This method differs to the direct DST method, since it involves inoculating with a culture that 
is isolated from a clinical specimen (Siddiqi et al., 2012). This means that the test can only be 
performed 3-6 weeks after the specimen was received, so that a culture could be isolated from 
the specimen (Siddiqi et al., 2012). This culture is then standardized and inoculated onto the 
growth media (egg based LJs, or Middlebrook agar) which contains the anti-TB drugs 
(Ramachandran and Parmasivan, 2003). A control is also included and it contains the drug 
free media which is then inoculated with the same standardised MTB culture.   
 
 
1 % Proportion method 
This method is often used as a reference or gold standard method for DST (NCCLS, 2003). It 
can be performed on agar based or egg based media and is inexpensive, simple, and does not 
require any equipment, except an incubator. The proportion method uses the principle of 
observing “growth or no growth” of the MTB culture when exposed to the concentration of 
the drug being tested (Richter et al., 2009). It makes use of just one concentration of the drug 
that is being tested. This concentration is the critical concentration, which is the lowest 
concentration that shows resistance, if growth of the bacilli is present (Heifets, 1991). The 
wild type strain does not grow when exposed to the critical concentration (Heiftes, 1991). 









the drug at its critical concentration. One of the dilutions should reveal colonies that can be 
counted (between 20-200 colonies). A control must also be included, which will follow the 
same procedure described above, but on drug free media. This is the DFC. The resistant 
proportion of MTB can then be interpreted as a percentage of the total proportion (obtained 
from the DFC).Resistance is defined if over 1 % of the bacterial population is able to grow 
when exposed to the critical concentration (Richter et al., 2009).The proportion method is 
time consuming and requires an incubation period of 3-6 weeks before results can be obtained 
(Ramachandran and Parmasivan, 2003).  
 
Absolute concentration method 
This method is also used frequently for DST, and is usually performed on LJs (Richter et al., 
2009). Reading of results and preparation of the culture inoculum are easy. It is based on 
inoculating a standardized inoculum of the test culture on drug free media and media that has 
various concentrations of the drug under test (Ramachandran and Paramasivan, 2003). Several 
graded concentrations of each test drug are used, and resistance is recorded as the lowest 
concentration of the anti-TB agent that is able to prevent the bacilli from producing colonies, 
which means inhibiting growth of the organism i.e. the minimum inhibitory concentration 
(MIC) (Ramachandran and Paramasivan, 2003). This method of testing depends on the 
viability of the organism (Ramachandran and Paramasivan, 2003), and is affected when using 
an inoculum of MTB that has many smaller sub-populations within it. This may result in 
incorrect results recorded. In order to prevent this, single colonies of the test organism should 
be prepared before running this DST, this would ensure presence of only that population of 
the MTB during the test. 
 
Agar Dilution Minimum Inhibitory Concentrations 
Agar dilution MICs are done in a similar manner. A serial dilution of the drug is made and 
different drug concentrations are incorporated into the Middlebrook agar plates. Then a 
standardised inoculum of the culture is added to this plate, and thereafter incubated for 3 
weeks. MIC determination offers more information than the DST, as it will not only reveal 
resistance, or susceptibility, but also the exact and smallest concentration at which no growth 










Resistance ratio method 
This DST method compares the growth of an unknown strain of MTB, to the growth of a 
known control strain such as H37Rv (Ramachandran and Paramasivan, 2003). Both of these 
strains are inoculated on media containing the same concentration of the drug that is being 
tested. After 3-6 weeks of incubation, results are read. Resistance is recorded as the ratio of 
the MIC of the unknown test strain to the MIC of the reference strain, specific for each set of 
drug dilutions (Ramachandran and Paramasivan, 2003). This method, like the absolute 
concentration method, is also affected by the viability and the inoculum size of the strain. 
Prior testing of the standard laboratory strain is important, to ensure that this strain exhibits its 
usual and known susceptibility pattern, and does not show any unexpected variation, as this 
will affect interpretation of results during the actual DST.  
 
E-test 
This test is a fairly new phenotypic DST. It makes use of plastic strips containing various 
concentration of the drug that is being tested. When this strip is placed on the surface of the 
culture media, one is able to determine the MIC, by noting the area of the strip that is able to 
inhibit the growth of the microorganism. The MIC is interpreted as the point where the ellipse 
intersects the e-test strip (Varma et al., 2002). This test can be performed on 7H10 
Middlebrook agar, and can usually yield results within 5-15 days (Richter et al., 2009). This 
method however is not very reliable and often has a high rate of displaying false resistance, 
when compared to BACTEC or the conventional proportion method (Ramachandran and 
Paramasivan, 2003). 
 
Mycobacteria Growth Indicator Tube (MGIT) 
MGIT is an example of a liquid based DST. There are two different types of MGIT tests, the 
manual BBL MGIT and the automated non-radiometric BACTEC MGIT 960 system. Both of 
these systems monitor the growth indicator tubes every hour, and are based on the same 
principle of detecting growth of the MTB in the tubes containing drugs compared to the drug 









consumption in the tubes which occurs when there is bacterial growth in the tubes (Richter et 
al., 2009). Acid fast bacilli (AFB) such as MTBn metabolize and use up oxygen, this in turn 
leads to the intensification of the oxygen quenched fluorescent dye which is present within the 
tubes (Springer et al., 2009). This indicator fluoresces under the 365 nanometer UV lamp 
(Adikaram et al., 2012; Piersimoni et al., 2006). The automated system will display a 
notification once a positive result is detected however the manual system requires that results 
are read manually. Results can be obtained between 7-10 days after incubation in the system. 
Both systems detect positives at the same rate, however the manual system can only be used 
for INH, RIF, EMB and SM, whereas the automated system can be used for these drugs as 
well as PZA. The latter also has software (Richter et al., 2009) for performing DST on SLD 
and new anti-TB drugs (Krüüner et al., 2006; Martin et al., 2008, Rodrigues et al., 2008; 
Rüsch-Gerdes et al., 2006). It has been used to determine the critical concentration of 
ofloxacin, moxifoxacin, prothionamide, LIN, CAP, AMIK, KAN and ETH. The sensitivity 
and specificity of the manual and automated system are very similar, and thus the manual 
system serves as a cheaper alternative if FLD are being tested. However the specificity of this 
DST is questioned. A number of factors may affect results obtained i.e. purity and 
homogeneity of the inoculum, the inoculum size and the environmental contamination that 
may occur during the inoculation process (Piersimoni et al., 2006).  
 
 
Microscopic Observation Drug Susceptibility (MODS) Assay 
This liquid based DST is a rapid, reliable and affordable tissue culture based assay that is well 
established for detecting resistance to INH and RIF (Shah et al., 2011). It can be performed 
using either sputum samples which are decontaminated or MTB culture (Richter et al., 2009). 
These are inoculated into a 24 well flat bottomed tissue culture plate containing 7H9 
Middlebrook broth and various concentrations of the anti-TB drug being tested. Thereafter 
plates are sealed and placed in plastic heat sealable bags, and incubated at 37°C. The plates 
have to be viewed daily from day 4 till day 21 for the detection of MTB, which displays a 
cording morphology in liquid media (Moore et al., 2004). This is done using an inverted light 
microscope. The plates are placed in plastic bags to reduce the risk of spills, as well as to 
contain the spill if it does occur within the bag. Since plates are moved in and out of the 









plastic bags prevents the spread of aerosols in the air, which is hazardous to laboratory staff 
(Singh et al., 2012). Results are obtained much faster with the MODS assay, compared to the 
conventional gold standard of DST on solid media, which takes 3 weeks to detect growth 
(Ejigu et al., 2008; Richter et al., 2009). This assay is also very sensitive in detecting both 
smear negative (Arias et al., 2007) and positive respiratory samples (Banerjee et al., 2008; 
Moore et al., 2006; Shiferaw et al., 2007). Another advantage of this assay is that it does not 
require a culture source to detect MTB. Instead it is capable of identifying MTB directly from 
sputum samples, as well as pleural fluids or the pleural biopsy (Tovar et al., 2008). MODS 
also detected MDR-TB successfully (Moore et al., 2006; Shiferaw et al, 2007). A downfall of 
the MODS assay however, is that it is less sensitive for detecting MTB in cerebro-spinal fluid 
(Caws et al., 2007), and it is unable to distinguish between MTB and non-tuberculosis 
mycobacteria. Thus it has low specificity for MTB. The latter is a major concern, as it will 
yield false positive results, and thus the MODS assay has to still be used in conjunction with a 
confirmation test such as microscopy. It also requires appropriate training for viewing of the 
plate. 
 
Colorimetric DST assays 
There are various types of colorimetric methods, some of the earlier types include the use of 
MTT salt as far back as 1983(Abate et al., 1998; Mosmann, 1983), and more recently, in 1995 
Yajko et al, (1995) used Alamar blue as an oxidation reduction indicator to detect MTB. 
These along with other colorimetric assays such as Malachite green and Resazurin microtitre 
assay (REMA) are easy to perform and interpret and results are reliable (Richter et al., 2009). 
They make use of consumables that are generally already present in the laboratory, thus 
making them inexpensive. They are based on colour changes which occur as a result of the 
metabolic activity of the MTB, and they do not require the use of specialised equipment, as 
these colour changes can be detected visually. 
  
Resazurin Microtitre Assay (REMA) 
REMA is a liquid based colorimetric DST that is used for the detection of MDR-TB strains 
(Palomino et al., 2002). It can be performed using decontaminated sputum samples or MTB 
culture. This assay is done in a sterile flat bottomed, 96 well plate. Broth is added to wells, 









achieve various concentrations of the drug. The MTB in a standardised liquid form is then 
added to the wells. A DFC and a control MTB strain with known susceptibility are included to 
ensure the test is performed correctly. The plates are incubated for 7 days at 37°C, and 
thereafter the resazurin is added to each well. A colour change from blue to pink indicates the 
growth of bacteria and also indicates the conversion of the oxidised state of resazurin to its 
reduced state (Palomino et al., 2002). The MIC is recorded as the lowest concentration of the 
drug that inhibits this colour change (Martin et al., 2003).This test shows good correlation 
with the results obtained from the proportion method. It has also been used successfully for 
DST using SLD (Martin et al., 2003). In an effort to reduce the production of aerosols this test 
can also be performed within screw cap tubes, however this then increases the cost of the test 
and makes it more labour intensive compared to working within a 96 well plate (Abate et al., 
1998; Foongladda et al., 2002; Martin et al., 2003). 
 
Nitrate reductase assay 
This assay was first described in 1989 by Emil Kalfin, and is based on the principle of MTB 
reducing nitrate to nitrite (Kalfin et al., 1989; Panaiotov and Kandtardjiev, 2002). It is used 
routinely for biochemical identification of mycobacterial species. The nitrate reductase agent 
has been recently changed, from the Griess reagent to a crystalline reagent, which is less toxic 
and has a longer shelf life (Lampe 1981; Panaiotov and Kandtardjiev, 2002; Warren et al., 
1983). This test is conducted in LJ tubes, which contains the drug at various concentrations, 
the MTB culture and the 0, 1 % potassium nitrate (KNO3). These tubes are incubated at 37° C 
for 7 days. From day 8 to day 10, the KNO3 is reduced when the crystalline reagent is added 
to the DFC tube, if a colour change occurs, then the crystalline reagent is also added to the 
tubes containing drugs, and the result are read. An isolate is considered to be resistant if a 
colour change from pink to red-purple occurs , and if this colour intensity is more than that in 
the 1: 10 diluted growth control (Ängeby et al., 2002). 
 
Malachite green 
This colorimetric assay is based on the ability of malachite green to show viability of MTB 
(Farnia et al., 2008). It has been used as a means of DST for SLD and TLD against MDR and 
XDR-TB strains (Farnia et al., 2008). Malachite green is a triphenylmethane dye. It is cheaper 









decontaminated sputum samples directly or MTB culture. In an effort to make this assay 
safer, and reduce the spread of aerosols, it can be conducted in microtubes with caps (Farnia 
et al., 2008) instead of 96 well plates. The microtubes which contain broth, and various 
concentrations of the drug being tested, are inoculated with the MTB culture and incubated 
for 7 days at 37°C.  The DFC tubes are tested first by the addition of the malachite green, at 
day 7, 14, or 21 or until a colour change takes place. The dye is originally a dark green colour 
in its oxidised form, which then converts to a colourless solution when in a reduced state. This 
only occurs when there is metabolism of MTB. The various time points were included as 
different strains of MTB metabolise at different rates. Once a colour change occurs in the 
DFC and indicates that sufficient metabolic activity has occurred, the malachite green can 
then be added to the tubes containing drugs and results can be read. 
 
The [(3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) assay 
This colorimetric method is similar to the ones described above, in that it is inexpensive, 
reliable, easy to perform and does not require sophisticated equipment to read results. It has 
been widely tested against various FLD (Abate et al., 1998; Mshana et al., 1998). This assay 
can be performed directly on decontaminated sputum samples or MTB cultures. It is based on 
the principle that live bacteria are able to use dehydrogenase to reduce the indicator (MTT 
salt) which is yellow in its oxidised state, to formazan, which is purple (Mosmann, 1983).The 
amount of formazan produced, is directly proportional to the number of live cells present 
(Mosmann, 1983). Results can be obtained after 10 days of incubation, when the MTT salt 
([(3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide) is added to the wells .A 
disadvantage of this assay, is that it is not specific for MTB and thus a colour change will still 
occur even if a contaminant is present in the well. This is due to the fact that any bacteria will 
be able to reduce the MTT salt. 
2.8.2 Genotypic methods 
Genotypic methods of DST, makes use of molecular techniques to detect mutations in specific 
target genes that are associated with conferring resistance to specific anti -TB drugs (Banerjee 
et al., 2008). Currently there are numerous genotypic methods that can be used i.e. 









hybridisation assays, PCR restriction fragment length polymorphism analysis (PRA), 
multiplex allele specific (MAS) PCR heteroduplex formation (Richter et al., 2009).  
These genotypic methods of DST are faster and are safer in that they do not require constant 
work with MTB culture, but rather with the MTB DNA. They are also able to determine 
resistance even if the sample has lost its viability. Most of them also involve reactions in an 
automated closed system thus reducing the introduction of contaminants (Richter et al., 2009). 
The disadvantages however, are that these methods are expensive, require specialised 
equipment as well as extensive training for laboratory staff (Banerjee et al., 2008). A further 
limitation is that only a portion of the genes associated with resistance for different anti -TB 
drugs and their sites of mutations have been revealed. These do not always confer resistance, 
as they are often absent in some resistant strains, or even present in susceptible ones. This 
implies the possibility of additional target genes being involved, but they currently remain 
undiscovered. False results may also occur due to contaminating amplicons or chromosomal 
DNA, especially when the same samples are used routinely or over long periods of time. 
 
Currently there are also two commercial DNA line probe assays that can be used for the 
detection of DR-TB. These are the strip assay INNO LiPA Rif.TB (Innogenetics, Belgium) 
and the MTB drug resistance genotyping test (GenoType MTBDR) assay (Hain Life Science, 
Germany) (Brossier et al., 2006). Either MTB cultures or direct clinical specimens can be 
used for both these methods. The ability for these assays to be performed using direct clinical 
specimens means that, the turn around time for results will also be faster than conventional 
methods which rely on cultures.The INNO LiPA Rif.TB has higher sensitivity and specificity 
when MTB cultures are used. This method targets the rpoB gene, and is thus able to detect 
resistance to RIF. The GenoType MTBDR method, which was introduced in 2004, is able to 
detect mutations in the rpoB and in addition the katG gene. It is thus able to detect resistance 
to RIF as well as high level INH resistance (Ling et al., 2008).  
 
There are two other variations of the Geno Type MTBDR method. This includes the 
MTBDRplus which is the second generation assay and the MTBDRsl assay. The former assay 
is able to detect mutations in the inhA gene, which confers to low-levels of INH resistance 
(Ling et al., 2008). Both of these Geno Type methods reveal excellent sensitivity and 









test to INH is low and varies (Ling et al., 2008). The GenoType MTBDR assay makes use of 
the following steps, DNA extraction, multiplex PCR, solid phase reverse hybridisation and 
detection of the resistant gene mutations (Hillemann et al., 2006;  and Hillemann et al., 
2007).This method is used in SA for routine diagnosis on selected clinical specimens and 
positive TB cultures (Ling et al.,2008). It has yielded ated results between periods of 6 hours 
to two days (Barnard et al., 2008). This is remarkably faster than the conventional method of 
DST’s, therefore making it a rapid screening tool, which aids in early iniatiation of treatment 
options.  
 
The MTBDRsl assay is a fairly new method which is capable of simultaneously detecting 
resistance to fluoroquinolones, ethambutol, aminoglycosides. It does this by recognising 
mutations in the gyrA, embB and rrs genes respectively. This assay is based on the same 
principle as the MTBDR assay, except it is now able to also detect resistance to SLD, and thus 
identify XDR-TB isolates. Studies have shown that this assay is specific for the above 
mentioned anti-TB agents, and that it is accurate in that manner. The sensitivity of this assay 
varies for the various anti-TB agents (Kiet et al., 2010).This method should not be exclusively 
used as a DST method. 
 
In 2010, WHO recommended the use of GeneXpert MTB/RIF (Xpert) as a first diagnostic test 
for patients suspected to have MDR-TB (WHO, 2010 Replaced with WHO, 2011c). This 
system is able to diagnose TB as well as detect resistance to RIF (Boehme et al., 2010; 
Boehme et al., 2011).It is the latest breakthrough in molecular genotypic methods and can be 
performed directly on sputum. Results are obtained within 2 hours (Piatek et al., 2013; WHO, 
2011c). This means that diagnosis of TB, as well as detection of resistance to RIF, can be 
made quickly and thus results in an overall decrease in time for treatment initiation. This 
method displays higher sensitivity than sputum microscopy in detecting MTB and is also able 
to detect smear negative MTB. It is similar in accuracy at detecting MTB to culture methods 
(Piatek et al., 2013; WHO, 2011c) Overall there have been many studies which have shown 
the high specificity and sensitivity of the GeneXpert for MTB (Scott et al., 2011). A 
disadvantage of this technique, as with all molecular based techniques, is that it is based on 
detecting DNA, and thus does not distinguish between live or dead mycobacteria (Meyer-Rath 









also expensive, and the cost of the actual machine is approximately USD17 000 (Piatek et al., 
2013). It then requires a cartridge for each test to be performed which costs USD 9. 98. The 
machine requires an uninterrupted supply of electricity and proper waste disposal is needed 
for the cartridges. As with most molecular techniques, technical support is required, and the 
laboratory staff needs to be appropriately trained.  
 
2.9 Time Kill Experiments (TKEs)  
TKEs are not methods of DSTs. Instead TKEs offer valuable information on the various anti -
TB drugs and their effect on MTB over a period of time (Budha et al., 2009). They can be 
used to understand how drugs behave in respect to its pharmocodynamics (PD) which is the 
drugs effect on the body (Budha et al., 2008). If TKEs were performed in vivo, using an 
animal model, one could also observe the pharmacokinetics (PK), which is how the body 
reacts to the drug (Budha et al., 2008). Past studies have conducted in vitro and in vivo TKEs 
using FLDs and some SLDs. TKEs are time consuming and laborious to perform, and require 
large quantities of consumables for the various time points. It is for these reasons that they are 
not performed routinely.  
 
TKEs can be performed in two manners, using various concentrations of each drug, and 
observing the PD at different time points, or by using a constant concentration of the drug, 
and still observing the PD properties at different time points. This study made use of the latter 
method, of a constant concentration. Although this may seem similar to the normal agar 
dilution method and MTT method, which also makes use of a static/constant concentration of 
the anti-TB drug, it differs in that it is not read at the end of the experiment, like the agar 
dilution and MTT methods. Instead of this “once off ” end point determined MIC, TKEs 
requires colony counts of the colony forming units (CFUs) to be counted at each time point. 
Since different dilutions were performed, the dilution which yields 20-200 colonies is chosen 
for each time point, for each of the drugs and for each of the isolates tested.  These colony 
counts enable one to observe the bactericidal activity of the various drugs over time, as well 
as to determine the degree at which the drug is able to kill (concentration dependant) ( Budha 
et al., 2008; Budha et al., 2009; Jayaram et al., 2003; Jayaram et al., 2004). Additionally 










MATERIALS AND METHODS 
This study was approved by the Biomedical Research Ethics Committee at the University of 
KwaZulu-Natal as per ethics approval number 274/09. 
3.1 Antimicrobial Drugs 
The antimicrobial drugs that were selected for testing in this study included capreomycin 
(CAP), para-aminosalicylic acid (PAS), linezolid (LIN), meropenem (MER), meropenem in 
combination with clavulanic acid (M&C).Whilst very little is known about the efficacy of 
these drugs against MDR and XDR-TB (WHO, 2008b), they are currently incorporated into 
the treatment regimens for the treatment of MDR and XDR-TB in SA. Thus DST and TKE 
information obtained from this study will assist in guiding the appropriate placement of these 
agents in the management of TB. Isoniazid (INH) was included as a control. All anti-TB 
agents used were purchased from Sigma Aldrich, USA, except MER and LIN which were 
donated for research use by AstraZeneca, South Africa and Pfizer, South Africa  
 
3.2 Mycobacterium tuberculosis isolates 
Based on susceptibility profiles, 12 MTB isolates were selected from the collection available 
in the TB laboratory of the Deapratment of Infection Prevention and Control at the University 
of KwaZulu-Natal. The isolates included:  
 2 fully susceptible 
 1 INH mono resistant 
 3 MDR 
 1 pre-XDR 
 5 XDR   
 
The isolates had previously been identified to species level by standard methodology and the 
susceptibility profile was determined by the 1% proportion method. H37Rv was used as a 










Table 4 provides the susceptibility patterns to the various anti-TB drugs that are used for 
classification in the different categories. 
Table 4 : Susceptibility Profile of MTB Isolates 
Isolate Name Susceptibility Profile 
 
INH RIF EMB STRE KANA OFLO 
Susceptible Isolates 
      H37Rv S S S S S S 
V4207 S S S S S S 
Mono resistant Isolates 
      V666 R S S S S S 
MDR Isolates 
      V1435 R R S R S S 
V2475 R R S S S S 
V4258 R R S R S S 
Pre XDR Isolates 
      R 413 R R S S R S 
XDR Isolates 
      R 26 R R S S R R 
R 252 R R S R R R 
R 502 R R S S R R 
R 506 R R S R R R 
KZN605 R R R R R R 




INH - Isoniazid 
 
STRE - Streptomycin 
RIF - Rifampicin 
 
KANA - Kanamycin 









3.3 Retrieval of Isolates from Storage 
The selected isolates were retrieved from storage in the -70 degrees Celsius (
o
C) freezer, and 
thawed to room temperature. These isolates were then revived, by inoculating 500 microlitres 
(µl) of the thawed stock into 5 millilitres (ml) of sterile Middlebrook 7H9 broth (Becton 
Dickinson and Company, Difco Laboratories, USA) (Appendix 1.1), using a sterile glass 
pasteur pipette. The broth contained the following antibiotics: polymyxin B (200.000 IU/L) 
(Sigma-Aldrich, USA), amphotericin B (20mg/L) (Sigma-Aldrich, USA), carbenicillin 
(100mg/L) (Sigma-Aldrich, USA) and trimethoprim (20mg/L) (Sigma-Aldrich, USA). These 
antibiotics are collectively referred to as PACT, and are incorporated into the broth to make it 
selective and reduce risk of contamination by non-mycobacterial organisms. The broth was 
also supplemented with oleic-albumin-dextrose-catalase (OADC) (100ml/L) (Becton 
Dickinson and company, USA). After inoculation, the tubes were incubated at 37 ° C for 3-6 
weeks.  
 
3.4 Culture onto Middlebrook 7H11 agar plates 
Once growth of the culture was observed in the Middlebrook 7H9 broth (Becton Dickinson 
and Company, Difco Laboratories, USA), a plastic sterile quadloop was used to transfer the 
broth and to perform a four way streak onto Middlebrook 7H11 agar (BD, Difco Laboratories, 
USA) (Appendix 1.2) plates. This was done to ensure that a single colony is obtained. This 
therefore ensures that a pure culture is used for the drug susceptibility tests, rather than a 
mixed culture. These plates were placed in a gas permeable plastic bag and heat sealed. It was 
thereafter incubated at 37°C for 3 weeks. Growth was observed after the 3 weeks, and 
thereafter a single colony was chosen, and inoculated into 5ml of sterile Middlebrook 7H9 
broth (Becton Dickinson and Company, Difco Laboratories, USA) (Appendix1.1) which 
contained PACT and OADC (Section 3.3). This was performed for all 11 isolates and H37Rv. 
The tubes of broth were then incubated at 37°C for 3 weeks. Once growth was observed in the 
tubes, after the incubation of 3 weeks, 200µl of this broth culture was aspirated using a sterile 
glass pasteur pipette, and inoculated onto Middlebrook 7H11 agar (BD, Difco Laboratories, 
USA) (Appendix1.2)plates. A sterile plastic quadloop was used to spread the broth evenly 
across the agar plate. For each of the 11 isolates and H37Rv, 5 Middlebrook 7H11 agar (BD, 









permeable plastic bag and heat sealed and incubated at 37°C for 3 weeks. After 3 weeks, the 
culture present on each plate were transferred into separate cryovials containing a storage 
media for TB culture (Appendix 1.3).These cryovials were stored at -70°C and were used as 
the stock culture for all isolates and H37Rv for all DSTs, TKE and genotypic methods that 
followed. 
 
3.5. Agar Dilution Method 
The agar dilution experiment was performed following the procedure outlined by Isenburg, 
(2004), with slight modifications. Results were read by observing if the agar plates had 
growth of MTB or no growth, and colony counts on the drug free control quadrants were 
performed. 
 
3.5.1 Preparation of Drug Solutions 
All anti-TB drugs were in their chemically pure powder form, and were stored at temperatures 
recommended by the manufacturer, until use. Various stock concentrations of each drug were 
prepared. These were prepared at double the required concentration (Appendix1.4.1-1.4.6), 
and to only reach the required concentration in 100ml of Middlebrook 7H10 agar (BD, Difco 
Laboratories, USA) (Appendix 1.6). Stock solutions of the anti-TB drugs were measured 
accordingly and dissolved in 10 ml of their appropriate solvent or deionised water. All anti-
TB drugs used were dissolved in deionised water except clavulanic acid, which was dissolved 
in 0.1M phosphate buffer at a pH of 6. (Appendix 1.4.1-1.4.6) The solutions were sterilized 
by membrane filtration using a Millipore 0.22 µm pore size filter unit (Merck Millipore, SA). 
From the stock solutions, 7 double dilutions were performed i.e. 10 ml of the first stock 
solution of the anti-TB drug (double the required concentration) was added to 10 ml of sterile 
appropriate solvent, this was mixed well and repeated 6 times for the next 6 dilutions to obtain 
the remaining concentrations .This was done for each anti-TB drug to achieve the 7 required 
concentration of each drug (Table 5). It is for this reason that a concentration higher than what 
is required, is made up at the starting point. Each dilution was then aliquoted into 1.1ml 
volumes in sterile cryovials tubes, and stored at -80 °C until use. For each drug, stock 









thawed, it was used immediately and any remainder was discarded and was not re-frozen or 
re-used. Working solutions of the anti-TB drugs for the MTT assay and the time kill 
experiment (TKE) were prepared freshly from the stock solution, and the necessary dilutions 
were performed to obtain the concentration for these 2 assays. This was also made possible by 
originally preparing a higher stock concentration i.e. each concentration of drug per 100 ml of 
media. 
 
Table 5: Concentrations of Anti -TB Drugs used for Agar and MTT Assay  
  Anti-TB Drug Concentration (µg/ml) 
  Isoniazid 0.062;0.125 ;0.25 ;0.5 ;1;2 ;4 
Capreomycin 1 ;2 ;4 ;8; 16; 32; 64 
Para-aminosalicylic acid 0.25 ;0.5 ;1; 2; 4; 8; 16 
Linezolid 0.125; 0.25; 0.5; 1; 2; 4; 8 
Meropenem 0.125; 0.25; 0.5; 1; 2; 4; 8 
Meropenem:Clavulanic Acid (0.25:8);(0.5:8);(1:8);(2:8);(4:8);(8:8);(16:8) 
    
 
3.5.2 Preparation of Agar Dilutions 
Middlebrook 7H10 agar (Becton Dickinson and Company, Difco Laboratories, USA) plates 
were prepared (Appendix1.6) and used for the agar dilution method. Briefly, appropriate 
amounts of Middlebrook 7H10 agar powder (19g/L), Bacto Casitone (Becton Dickinson and 
Company, Difco Laboratories, USA) (1g/L) were incorporated into 90ml of deionised water. 
This was then dissolved using a magnetic stirrer and placed on a magnetic plate. Thereafter, 
glycerol (5 ml/L) (Merck, SA) was added and this suspension was autoclaved for 15 minutes 
at 121
o
C using the media setting. This was left to cool in a water bath at a temperature of 55 
°C. When this media reached the water bath temperature, OADC (Becton Dickinson and 
company, USA) was added (100ml/L). M&C were not tested with the agar dilution method 









have inactivated the ß-lactamase inhibitor. Since MER was used as a control for M&C, this 
drug was also not tested using the agar dilution method. These two drugs were investigated 
using the MTT assay method. 
 
The remaining 4 pre-aliquoted anti-TB drugs were then thawed, and 1 ml of each antibiotic 
was added to the 100ml of agar, to obtain the desired test concentration. The mixture was 
swirled gently, and a repeater pipette (Eppendorf), was used to transfer 5ml of the agar into 
the quadrants of quadrant Petri dishes. This step was performed 7 times for each anti-TB drug. 
Each time, a different concentration of the anti-TB drug was added to the media, till all 7 
concentrations were completed. A drug free control (DFC) was also prepared. The agar plates 
were allowed to solidify before use. Remaining plates were stored at 4°C, but were used with 
a week of preparation.  
 
3.5.3 Standardisation of the Inoculum 
Colonies from a 3 week old 7H11 Middlebrook agar (Appendix 1.2) plate of culture was used 
for the standardization step for each of the 11 isolates and H37Rv. Briefly, confluent growth 
covering an entire 7H11Middlebrook agar plate (diameter 65cm) was harvested and 
suspended into a tube containing 0,5ml of sterile phosphate buffer saline (PBS) (Sigma-
Aldrich, USA) (Appendix 1.7) with 0.05 % Tween 80 (Merck, SA) (Appendix 1.8) and 4 
glass beads (approximately 5mm in diameter). The tubes were agitated for 2 minutes using a 
vortex and remaining clumps were allowed to settle for 15 minutes. Therafter, 3ml of PBS 
solution containing  0.05 % Tween 80 (Merck, SA) was then added to the tubes, which were 
agitated for a further 5 minutes. The remaining clumps were allowed to settle for 45 minutes. 
The top layer of culture was removed using a sterile glass pipette and discarded.The 
remaining contents within the tube was mixed with sterile triple distilled water to match an 
optical density of McFarland BaSo4 suspension No 1(Appendix 1.10). Three 10-fold serial 
dilutions (0.5ml of the suspension into 4.5 ml of sterile distilled water) were made to prepare 
the required inoculum concentration of 10
-4 










3.5.4 Inoculation of plates 
The Middlebrook 7H10 agar (Becton Dickinson and Company, Difco Laboratories, USA) 
plates containing the 7 different concentrations of the anti-TB drugs in separate quadrants, 
were then seeded with 100µl per quadrant of the standardised MTB cultures (Section 3.5.3). 
The same volume of a 10-fold dilution of the inoculum (10
-3
cfu/mL) was used for the drug 
free controls. This further dilution was used for the DFC, to ensure that a countable number of 
colonies (20-200) were achieved. All agar plates were swirled gently to evenly distribute the 
inoculum over the agar. Plates were allowed to stand for 30 minutes, before they were 
incubated at 37° C for 3 weeks, in heat sealed gas permeable plastic bags.  
 
3.5.5 Interpretation of results: 
At day 21 the plates were removed from incubation and results were read. Growth was 
recorded as either being present or not. The lowest concentration of the 4 anti-TB drugs that 
inhibited growth (MIC) was noted. Colony counts of the DFC quadrants were performed and 
recorded. 
 
3.6 MTT Reduction Assay  
This assay was chosen in an effort to determine how accurate it is to the gold standard, agar 
dilution method. Although there is a lack of guidelines and standardized protocols when 
testing SLDs and TLDs, the information gained from using the MTT assay and comparing it 
to the agar dilution method can be used to aid in its validation. In regions of high TB and HIV 
co-infection, the WHO recommends the use of validated liquid DST’s when testing SLDs and 
TLDs (WHO, 2008b). For this assay to be validated, it is required to be easy to perform, 
rapid, safe, reliable and cost effective. The MTT assay meets all of these requirements, 
however the sensitivity and specificity of this method when using the anti-TB agents that 
were chosen for this study, remains unknown. Thus a comparison between the MTT assay and 
the agar dilution assay needs to be made, to determine if these two methods provide accurate 









3.6.1 Preparation of the test plate  
 The MTT assay was performed in a sterile Greiner CELLSTAR 96-well, flat bottomed 
microtitre plate (Sigma-Alrdich, USA). Since this assay requires incubation for a period of 9 
days at 37 °C, 100 µl of sterile distilled water was added to the peripheral wells around the 
plate to prevent drying out. The assay was performed following the methodology illustrated in 
Abate et al, (1998), with slight modifications. 
 
 Briefly 100µl sterile Middlebrook 7H9 broth (Becton Dickinson and Company, Difco 
Laboratories, USA) (Appendix 1.1) was inoculated into the inner wells from left to right of 
each row (100µl/well). The initial stock concentration for each of the anti-TB drugs were 
prepared to reach the desired concentration in 100ml of media for the agar dilution method 
(Section 3.5.1) (Appendix 1.4.1-1.4.6),therefore these were now too concentrated for the 
small volumes of broth used in the MTT assay. Appropriate dilutions were performed to reach 
double the desired highest concentration of each drug in 200µl (total final volume in each 
well of the 96 well plates). Once this concentration of double the highest concentration was 
made, 100 µl of it was added to the first well, which already contained 100µl of 7H9 
Middlebrook broth. Therefore a double dilution was performed within the first well of the 96 
well plate to achieve the highest required concentration, thereafter six two-fold serial dilutions 
of the antimicrobial agents in 7H9 Middlebrook broth were performed (across the row, from 
left to right) (final volume 100 µl/well). Once all 7 concentrations were achieved, the last 
100µl of the broth and drug solution is discarded. This step (6 dilutions down the row) was 
not carried out for clavulanic acid, as it required a constant concentration of 8µg/ml when 
incorporated with meropenem (Table 5), therefore this concentration was added to each of the 
M&C wells directly. The inoculum for each isolate was standardised as described above 
(Section 3.5.3) and 100 µl containing 10
-4 
cfu/ml were added to each well (which gives the 
total final volume of 200µl in each well). Each row included a drug free control and each 
plate included a well with broth only. All broth used during drug susceptibility testing did not 
contain PACT or PANTA, as this would affect the results obtained, as they may play a role in 
inhibiting growth of MTB, or may even interact with the MTT salt. The plates were held 
together securely using elastic bands and they were then heat sealed in a gas permeable plastic 
bag and incubated at 37° C for 7 days. On day 8, the plates were removed from the incubator 









dimethylthiazol-2-yl]-2, 5- diphenyltetrazolium bromide (5mg/ml) (Sigma-Aldrich, USA) 
(Appendix 2.1) was added to each well. The plates were then sealed once again, as described 
above and re-incubated overnight at 37
o
C. On day 9, 50µl of the formazan solubilisation 
buffer which is a SDS-DMF solution (Appendix 2.4) was added to each well and the plate 
was sealed and re-incubated overnight. This was a 1:1 volume of the 20 % Sodium Dodecyl 
Sulfate (SDS) (Sigma-Aldrich, USA) solution (Appendix 2.2) and a 50% aqueous N,N 
Dimethylformamide solution  (Sigma-Aldrich, USA) (Appendix 2.3). On day 10, if no colour 
change was observed in the un-inoculated broth, the test was ready for reading. Each isolate 
was tested in triplicate. 
3.6.2 Interpretation of MTT assay results  
A yellow colour indicated growth inhibition, and a colour change to purple indicated actively 
metabolizing cells. The lowest concentration of the antimicrobial agent that showed growth 
inhibition (yellow) was recorded as the MIC. 
 
3.7 Time Kill Experiments (TKEs) 
Due to the labour intensive nature of time kill experiments (TKEs), only 6 isolates were used. 
The isolates selected were chosen according to their susceptibility profile, and included: 1 
susceptible, 2 MDR-TB and 2 XDR-TB isolates, with H37Rv as a control strain. These 
isolates were V4207, V1435, V4258, KZN605 and R252 (susceptibility profile available in 
Table 4). This experiment was conducted following the methodology outlined by a protocol 
provide by Dr Catherine Vilchèze of Albert Einstein College of Medicine, USA. 
TKEs were performed for each drug at a concentration twice that of the MIC as determined 
by the agar dilution methodology (Section 3.5). Bacterial suspensions with a 1 McFarland 
(Appendix 1.10), density were prepared for each isolate. This was done following the 
standardisation method explained in section 3.5.3. Different volumes (0.5 ml; 1ml; 1.5ml and 
2ml) of this suspension for each of the 5 isolates and H37Rv were added to sterile Nalgene 
plastic inkwell square bottom bottles (Thermo Fisher Scientific, USA) containing 15 ml of 
Middlebrook 7H9 broth (Becton Dickinson and Company, Difco Laboratories, USA) 









(Sigma-Aldrich, USA) was added to the media, to prevent the MTB cultures from clumping 
as they grew. The bottles were incubated at 37 ° C, in an Innova 44 Orbital shaker incubator 
(New Brunswick Scientific,USA) at a speed of 150 rpm and the optical density (OD) of each 
culture was read daily from day 3 onwards using a spectrophotometer, at a wavelength of 
600nm. Once an OD of 0.7 was obtained, the suspension was diluted 15 times i.e. by adding 3 
ml of the suspension to 42 ml of sterile Middlebrook 7H9 broth. This new suspension was 
then agitated, and further divided into 10 ml aliquots in inkwell bottles. Anti-microbial drugs 
were added at the required concentration for each drug (at double the MIC obtained during the 
agar dilution and the MTT assay). This concentration was obtained after further diluting from 
the stock solution prepared in Section 3.5.1.  It was calculated to be twice that of the MIC 
obtained (for each isolate with the corresponding anti-TB drug) in a total volume of 10ml 
Middlebrook 7H9 broth (in the inkwell bottles). Each isolate was tested in triplicate for each 
drug. For each of the triplicate runs, a fresh culture was grown up and used for each isolate, 
and new dilutions of the anti-TB drugs were prepared from the concentration of the working 
solution (Appendix 1.4.1-1.4.6).  
On days 0, 3, 7, 14, 21 and 28 growth was quantified. After continuous agitation at 150 rpm 
within a shaker incubator (New Brunswick Scientific, USA), 10-fold serial dilutions were 
made with the culture suspension. This was done by adding 100µl of the culture suspension of 
each isolate to 900 µl PBS with 20% (v/v) tyloxapol (Appendix 3.2). This was done 5 times to 










. From each of the 5 dilutions 
above, 50 µl was removed and plated out in duplicate on separate Middlebrook 7H11 agar 
plates. The plates were heat sealed in gas permeable plastic bags and incubated for 3 weeks at 
37° C. This procedure was done at each of the 6 time points for each of the selected isolates 
and their 5 anti-TB drugs.   
 
Plates containing a countable number of colonies (between 20 and 200) were used to perform 
colony counts. Raw data of these colony counts are present in Appendix 7. Once the colony 
counts were performed, the data was used to construct the time-kill curves (Section 4.2.1). 
The number of colony forming units per ml (cfu/ml) was calculated by multiplying the 
counted number of colonies by 20 X the dilution factor. The exact formula used is described 









used to construct the time kill curves. The raw data of the average log values for the various 
time points are provided in Appendix 6  
 
3.8 Detection of mutations in genes coding for drug targets 
3.8.1 Culture prior to DNA Extraction:  
The 11 clinical isolates (Table 4) and H37Rv were sub-cultured onto Middlebrook 7H11 agar 
(BD, Difco Laboratories, USA) plates (65mm). These plates were then sealed in plastic heat 
sealable bags and incubated at 37°C for 3 weeks. 
3.8.2 DNA Extraction:  
DNA extraction was performed using the N-acetyl-N, N, N-trimethylammonium 
bromide(CTAB) method. The procedure was carried out as previously described by Van 
Soolingen et al, (1991), with slight modifications. 
 
The growth of each of the 11 isolates and H37Rv was harvested from the 65mm agar plates 
(Section 3.8.1), using a sterile loop, and suspended in a 2ml microfuge tube (Eppendorf) 
containing 50 µl of lysozyme (Sigma-Aldrich, USA) of concentration 10mg/ml (Appendix 
4.2). The suspensions were placed in a water bath at 37°C for 1 hour. The tubes were then 
removed, and 75 µl of a proteinase K (Roche Diagnostics, Mannheim, Gemany) of 
concentration 10mg/ml (Appendix 4.3) and 10 % Sodium Dodecyl Sulfate (SDS) (Sigma-
Aldrich, USA) (Appendix 4.4) solution was added to each of the tubes. The tubes were then 
thoroughly mixed with the reagent by vortexing and the tubes were incubated in a water bath 
at 65 °C for 10 minutes. Following this, 100 µl of 5M Sodium chloride (NaCl) (Sigma-
Aldrich, USA) (Appendix 4.5) was added to each tube and vortexed for a few seconds. 
Thereafter, 100µl of pre-warmed (65°C) CTAB-NaCl (Sigma-Aldrich, USA) (Appendix 4.6) 
solution was added to the tubes. These suspensions were agitated using a vortex until the fluid 
turned milky. This was followed by incubation at 65˚C for 10 minutes. Next, 750µl of a 
chloroform (Sigma-Aldrich, USA): isoamyl alcohol (Sigma-Aldrich, USA) (24:1) mixture 
(Appendix 4.7) was added to the tubes. The fluid was agitated for 10 seconds, and then 
centrifuged for 20 minutes at 12 000rpm. The supernatant was transferred to a sterile 1.5 ml 









After gently mixing by inverting three times, the contents of each tube were then observed for 
the formation of a thin thread. If this was present, the mixture was centrifuged for 30 minutes 
at 12 000rpm. Thereafter, the isopropanol was discarded. The pellet was washed in 1 ml 70 % 
cold ethanol (Merck, SA) (Appendix 4.8). Tubes were inverted and then centrifuged for 5 
minutes at 12 000rpm. The ethanol was discarded, and the pellet was washed again, but now 
with only 500 µl of 70 % ethanol (Merck, SA). After centrifugation and removal of the 
ethanol (as described above), the pellet was allowed to dry by evaporation for about 30 
minutes at room temperature. Depending on the size of the pellet, 20 to 50 µl of 1x TE buffer 
(Tris-ethylenediamine tetra acetic acid or EDTA) was added (Appendix 4.1). The DNA was 
mixed in the buffer by inversion. The DNA was then stored in the fridge at 4°C until use. 
 
3.8.3 Gel Electrophoresis 
The concentration and quality of the DNA was determined by means of gel electrophoresis. A 
1% agarose gel (Lonza, USA) (Appendix 4.9 ) was prepared by mixing agarose with 1 x Tris-
borate-EDTA buffer (TBE buffer) (Appendix 4.10). To dissolve the agarose, the mixture was 
heated in a microwave oven. The solution was allowed to cool to 40-45
o
C, after which 
ethidium bromide (Sigma-Aldrich, USA) (Appendix 4.11) was added. This was then poured 
into a gel casting tray, which was secured with masking tape on each end, to prevent the gel 
from leaking out of the tray. Attached within the casting tray, was a 20 well plastic comb. 
Once the gel was poured into the casting tray with the comb securely attached, it was left to 
solidify for 30-40 minutes at room temperature after which the combs and tape were removed. 
The gel was placed in an electrophoresis tank (Hoefer) filled with 1 X TBE buffer (Appendix 
4.10). On a sheet of parafilm, 5 µl of DNA of each isolate was mixed with 3 µl of gel loading 
dye (Appendix 4.12). This was then pipetted into the corresponding well of the gel. One well 
was used for the 6XMassRuler Low range DNA ladder (Fermentas, Thermoscientific, 
USA).This was included to serve as a molecular weight marker, so that the quantification and 
sizing of the DNA fragments on the agarose gel could be determined. An electrical current of 
100 volts (V) was applied to the gel for 30-45 minutes. Thereafter, the gel was removed from 
the tank, and an image of the bands was captured by using the Syngene gel imaging system 









The size and brightness of the bands were compared to that of the molecular weight marker. 
This was used as a crude measurement for the quality and concentration of the DNA which 
was then diluted with nuclease free water to achieve optimal concentrations. The dilutions 
were stored in the fridge at 4˚C till further processing. 
 
3.8.4 Polymerase Chain Reaction (PCR)  
Genomic DNA that was isolated from the 11 MTB isolates and H37Rv (Section 3.8.2) was 
used as the target DNA, to determine possible mutations at specific genes that confer 
resistance to the related anti-TB drugs. PCR was performed using the Expand High Fidelity 
PCR System kit (Roche Diagnostics, Germany). All reagents for the PCR reaction were 
provided by this kit. However, the optimal concentrations of the various constituents had to be 
determined, i.e. the optimal concentration of the enzyme or the MgCl2. These factors together 
with optimising the actual PCR conditions, such as temperature at which the reaction is run 
and the duration of the cycles etc. are very important. They will impact on the final PCR 
product that was amplified and obtained.  
 
Details of primers, PCR conditions and mastermix used are shown in tables 6, 7 and 8 
respectively. The mastermix components (Table 8) were aliquoted into PCR tubes (placed on 
ice) and the specific DNA for each of the isolates and H37Rv were added to these tubes as 
well. The primers that were used for each reaction are displayed in Table 6. The PCR reaction 
took place within a thermocycler (Applied Biosystems, USA) and the cycling conditions used 
for the various runs are displayed in Table 7.  
 
After each PCR experiment, gel electrophoresis was performed, following the same procedure 
as described above (Section 3.8.3). This was done to detect the presence of a band, within the 
molecular marker range, which indicated that the PCR was successful. These PCR products 











         
Table 6 : Primer Details for target genes 
         
Gene    Primer Details     
         
rrs Region 2   1400rrs                                                                                                                                  Fwd:KMSA [AAGTACCCCGCCTGGGGAGTACGG]
   Rev:KMRA [GGTGGGACAACACCTGGAACAAGTC] 
   Jugheli et al., 2009.  
         
tlyA: Region 1  Fwd: tlyA1[AAGGCATCGCACGTCGTCTTTCC]  
   Rev: tlyA2 [TGTCGCCCAATACTTTTTCTACGC] 
   Designed using PRIMER3    
         
thyA: Region 1  Fwd: thyA [GCCTCCGTTGTACTCCTGTG]  
   Rev: thyA  [ACACGCGTCACTCCTTGATT]  
   Designed using PRIMER 3    
         
rrl: Region 3                                                                                                                                     Fwd: rrl5 [GGTTGAAGACTGAGGGGATGAG]
   Rev: rrl 6 [GCCTTAGGTCCCGACTCACCCT]  
   Richter  et al., 2007  
    
         
rrl: Region 5     Fwd: rrl 9[CCCAAACCGACACAGGTGGTCA]  
   Rev: rrl10[AAACTACCCGCCAGGCACTGTC]  
   Richter  et al. 2007.  













       
Table 7 : PCR Conditions for genes of interest 
       
Gene    PCR Cycling Conditions  
       
rrs Region 2 1400rrs  Initial Denaturation:                    5mins @94ºC 
   The next 3 steps had 40 cycles:  
   Denaturation:                                 45s @ 94 ºC 
   Annealing:                                      45s @ 66ºC                    
   Extension:                                        45s@72ºC    
   Final Extension:                      10mins @ 72 ºC 
   Amplicon Size:                                       831bp           
       
tlyA   Initial Denaturation:                 2 mins @ 94ºC 
   The next 3 steps had 40 cycles  
   Denaturation:                                 45s @ 94 ºC   
   Annealing:                                     45s @ 60 ºC                 
   Extension:                                       45s @ 72ºC           
   Final Extension:                      10mins @ 72 ºC 
   Amplicon Size:                                      981 bp 
       
thyA   Initial Denaturation:                   5mins @ 94ºC 
   The next 3 steps had 40 cycles   
   Denaturation:                                 45s @ 94 ºC  
   Annealing:                                      45s @62 ºC               
   Extension:                                       45s @ 72ºC            
   Final Extension:                      10mins @ 72 ºC 
   Amplicon Size:                                        981bp 















Rrl :Region 3 Initial Denaturation:                   5mins @ 94ºC 
   The next 3 steps had 40 cycles.  
   Denaturation:                                 45s @ 94 ºC  
   Annealing:                                     45s @ 59 ºC                 
   Extension:                                       45s @ 72ºC            
   Final Extension:                      10mins @ 72 ºC 
   Amplicon Size:                                        594bp 
       
Rrl: Region 5  Initial Denaturation:                   5mins @ 94ºC 
   The next 3 steps had 40 cycles:  
   Denaturation:                                45s @ 94 ºC  
   Annealing:                                      45s @ 59ºC            
   Extension:                                      45s @ 72ºC   
   Final Extension:                      10mins @ 72 ºC 
   Amplicon Size:                                        623bp 



















Table 8:  PCR Mastermix for Genes of Interest 
      Gene Mastermix (1 reaction ) 
 
     rrs: Region 2 -1400rrs 1.Buffer (10X):                                 5 µl 
tlyA: Region 1 2.MgCl2(25nM):                                    3 µl
rrl: Region 3 3.dNTPs(10mM each):           1 µl 
rrl: Region 5 4.Primer Fwd (10pmol):       1 µl 
  
    Primer Rev (10pmol):        1 µl 
  
5.Enzyme(2.5 U):                       0.75 µl 
  
6.Water:                                                35.95µl  
  
Total Volume:                        48 µl 
  
                                          + 2 µl DNA 
      thyA: Region 1 
 
1. Buffer (10X):                          5µl 
  
2.MgCl2(25nM):                    3,3 µl 
  
3.dNTPs(10mM each):           1 µl 
  
4. Primer Fwd (10pmol):      1 µl 
  
    Primer Rev (10 pmol):        1µl 
  
5.Enzyme(2.5 U):                       0.45 µl 
  
6.Water:                              36.25 µl 
  
Total Volume:                        48 µl 
  
                                          + 2 µl DNA 









3.8.5 PCR Product Purification 
The PCR products were purified using the Invitrogen PureLink PCR purification kit (Version 
A) (Life Technologies, USA).The manufacturer’s instructions were followed. Briefly, 3 main 
steps were conducted: DNA binding, DNA washing and DNA eluting. The binding step 
involved making a 4:1 solution of PureLink binding buffer with isopropanol and the PCR 
product. The combination was thoroughly mixed and then added to the PureLink spin 
columns that were provided. The columns were centrifuged for 1 minute at 10 000 X g or 
9092rpm. The flow through was then discarded and the spin column was placed into a 
collection tube. The spin column remained in the collection tube, awaiting the DNA washing 
step. Wash buffer was combined with 100 % ethanol. Six hundred and fifty microlitres of the 
mixture was added to the column. The column was then centrifuged again for 1 minute at 
10000 X g or 9092 rpm. The flow through was discarded and the spin column was placed in 
the collection tube. The column was then centrifuged for 2-3 minutes at 12 000X g or 9960 
rpm. This was done to remove any residual wash buffer. The collection tube was discarded, 
but the spin column was kept, awaiting DNA elution. For DNA elution, the column is placed 
in a clean 1.7 ml PureLink elution tube. Thereafter, 50µl sterile distilled water was passed 
through the centre of the column. The column was incubated at room temperature for a 
minute, and thereafter centrifuged for 2 minutes at 12 000Xg or 9960 rpm. The spin column 
was then discarded, as the purified PCR product was moved into the elution tube during 
centrifugation. This purified PCR product within the elution tube is the final product and was 
stored in a freezer at -20˚C, until further use. 
 
3.8.6 Preparation before Sequencing:  
A reaction was performed on the PCR products (Section 3.8.5) before sequencing occurs. It 
was performed to purify the sequencing template and removes unwanted primers and dNTPs 
which may destroy the sequencing reaction. This was performed using the ABI Prism BigDye 
Terminator v3.0 Cycle sequencing ready reaction kit (Applied Biosystems, USA).This step 
requires 2.5µl of DNA which must be a final concentration of 20ng/µl of the DNA to be used 
for each reaction. A mastermix comprising of the reagents provided by the kit (5 X 









(specific for each of the target genes mentioned earlier) and water. These were added to a 
MicroAmp96 well reaction plate (Applied Biosystems, USA), and was placed in a 
thermocycler, under the following conditions: 1 cycle at 96˚C for 1 minute. 
25 cycles of the following 3 steps: 
96˚C for 10 seconds 
50˚C for 5 seconds 
60˚C for 4 minutes 
The last cycle is a hold cycle at 4˚C. 
Once this step was completed, the plate with the sequencing reaction product was cleaned. 
 
3.8.7 Sequencing Plate Clean-up 
A 3 M sodium acetate (Appendix 4.13) (Applied Biosystems, USA) of pH 5.2 (5µl) and 100% 
ethanol (50µl) (Merck, SA) solution was constituted and added to each well containing the 
sequencing reaction products. The sodium acetate is responsible for precipitating the DNA 
from the ethanol. The plate was then sealed with an adhesive foil cover (Thermowell sealing 
tape) (Corning, USA) and agitated using a vortex. Thereafter, the plate was centrifuged for 20 
minutes at 3000Xg or 4980 rpm. The foil cover was then removed and the plate inverted in a 
quick, smooth motion onto a folded pad of paper towels. This step was done with great care, 
as handling the plate to roughly would have resulted in the pellet being dislodged. The 
inverted plate on the paper towel was placed into the centrifuge for 1 minute at 150Xg. The 
plate was immediately removed and 150 µl of cold 70 % ethanol (Merck, SA) (Appendix 4.8) 
was added to each well. The plate was re- sealed with an adhesive foil cover, and agitated 
using a vortex. Thereafter it was centrifuged for 5 minutes at 3000Xg or 4980 rpm. The plate 
was then inverted on a folded paper towel again and centrifuged at 150Xg for 1 minute. The 
plate was removed from the centrifuge, and placed on a thermocycler (Applied Biosystems, 
USA), where it was left to dry for 5 minutes at 50˚C. After drying the plate, it was sealed with 
an adhesive foil cover, and then the entire plate was wrapped in foil, to protect the dyes from 










3.8.8 Sequencing using the 3130 XL Genetic Analyser. 
The plate was removed from the freezer, and samples were re-suspended in 10µl highly-
deionized (Hi-Di) formamide (Applied Biosystems, USA) and thereafter agitated thoroughly 
using a vortex. The PCR products were then denatured, by placing in a thermocycler (Applied 
Biosystems, USA) at 95˚C for 3 minutes and at 4˚C for a minimum of 3 minutes. The plate 
was then sequenced in the 3130 XL Genetic analyser (Applied Biosystems, USA) and 


























This section describes the findings of the agar dilution experiment and the MTT assay (Table 
9). It then describes results of the time kill experiments (Figures 1-11) for 5 specific isolates 
and H37Rv and lastly this section describes the sequencing results for the 4 different target 
genes encoding the drug targets for the specific anti-TB agents used (Table 11). 
 
4.1 MIC Interpretation (Refer to Table 9) 
H37Rv displayed an average INH MIC of 0.125 mg/L with both methods of DST. The 
susceptible isolate V4207 showed an MIC in the agar dilution test of 0.25 mg/L and in the 
MTT test of 0.125 mg/L. This is within the acceptable range of one dilution difference. 
According to WHOs breakpoint concentrations (Table 10), (WHO, 2009) for INH in agar 
(0,2mg/L) and in broth (0,1mg/L) both H37Rv and V4207 would be considered susceptible to 
INH. The mono-resistant, MDR-TB, Pre-XDR-TB and XDR-TB isolates all have the same 
MIC value for INH in both test methods, of 8mg/L. Thus based on the WHO breakpoint 
concentration (2009) (Table 10), they would be resistant to INH.  
 
When exposed to CAP, H37Rv has a MIC value of 4 mg/L for both test methods. V4207 
(susceptible isolate) has a MIC value of 8 mg/L in agar and 4 mg/L in the MTT assay. Based 
on the WHO breakpoint concentrations (Table 10) for CAP of 10 mg/L in agar, and 2,5 mg/L 
in broth, both H37Rv and V4207 would be considered susceptible to CAP with the agar 
dilution method but resistant with the MTT assay. The MIC for the INH mono resistant 
isolate (V666) and some of the MDR-TB isolates (V1435 and V2475) are 8 mg/L with agar 
dilution and 4 mg/L with MTT. V4258 (MDR-TB) has an MIC of 4 mg/L in agar, and 
according to the breakpoint concentrations, this would make it together with V666 (INH 
mono resistant), V1435 (MDR-TB) and V2475 (MDR-TB) susceptible to CAP. With the 
MTT assay V4258 (MDR-TB) has an MIC of 2 mg/L and is thus susceptible with both 
methods, whereas the rest are resistant with the MTT assay. The pre-XDR-TB isolate, R413, 
has a MIC of 8 mg/L for both agar and MTT. These MIC values thus make it susceptible to 









KZN605) except R252 have the same MIC for agar (32 mg/L) and broth (8 mg/L). R252 has a 
lower MIC value for both methods i.e.8 mg/L in agar and 4 mg/L in broth. Despite this 
difference in MIC value, all XDR-TB isolates are considered resistant to CAP with both broth 
and agar methods.  
 
The MIC values obtained for PAS using the MTT assay were markedly lower than the MIC 
values obtained by the agar dilution method. Experiments using the MTT assay method were 
repeated up to 5 times, and always obtaining inconsistent and lower values, that were far from 
those obtained by the agar method. Both H37Rv and V4207 (susceptible) have an MIC of 2 
mg/L, which are the same as the breakpoint concentration as described in the WHO 
Guidelines. The INH mono resistant isolate V666, had a MIC for PAS of 0.5 mg/L, and 
according to WHO, can be considered susceptible. Two of the MDR-TB isolates (V1435 and 
V2475) have an MIC value of 2 mg/L, which is also the same as the breakpoint concentration. 
The remaining MDR-TB isolate, V4258, has a lower MIC of 1 mg/L, thus making it 
susceptible to PAS. Pre-XDR-TB isolate, R413 and XDR-TB isolates (R26 and R502) have 
MIC values of 4 mg/L, thus making it resistant to PAS. The remaining XDR-TB isolates 
(R252, R506 and KZN 605) have MIC values of 2 mg/L, which is the breakpoint 
concentration of PAS in an agar medium (WHO, 2009) (Table 10). 
 
Linezolid MICs varied between 0.5mg/L and 0.25mg/L for all isolates with the lowest MICs 
obtained in the MTT assay. According to the WHO criteria (WHO, 2009), all isolates are 
deemed susceptible (Table 10). 
 
Meropenem on its own has no activity against MTB. It was still tested as a control for M&C 
and all MIC values were 16mg/L, which was the highest concentration that was tested. It can 
thus be dedused that MTB would still grow at higher concentrations of meropenem on its 
own, if higher concentrations were tested. When meropenem is combined with clavulanic acid 
(M&C), however, it shows great anti-mycobacterial activity against MTB when using the 
MTT assay. The MICs in the MTT assay for all but one isolate varied between 0.5 and 1 
mg/L. This value is at the breakpoint concentration as suggested by WHO (Table 10). V1435 









mg/L, thus suggesting that it is resistant to meropenem in combination with clavulanic 
acidThe MICs that were obtained using the agar dilution assay, for M&C were not used, as 
clavulanic acid is sensitive to heat, and thus its activity against MTB is affected when it is 
exposed to the high temperature of the 7H10 agar during plate preparation.  
 
Table 9 displays the MICs that were obtained using the MTT assay and the agar dilution 
method, when the 5 anti-TB agents were tested against the 11 TB isolates and H37Rv. 
 
Raw data of all MIC values obtained during the agar dilution and MTT assay are shown in 






















Table 9: MIC values of Agar Dilution and MTT Assay 
MIC of Isolates/Strains µg/ml 
        MIC Method Isolate/Strain INH CAP PAS LIN MER M&C 
        Agar H37Rv 0.125 4 2 0.5 16 32 
MTT H37Rv 0.125 4 0.5 0.5 16 1 
        Agar V4207 0.25 8 2 0.5 16 32 
MTT V4207 0.125 4 0.5 0.5 16 1 
        Agar V666 8 8 0.5 0.5 16 32 
MTT V666 8 4 0.25 0.5 8 1 
        Agar V1435 8 8 2 0.5 16 32 
MTT V1435 8 4 0.5 0.25 16 2 
        Agar V2475 8 8 2 0.5 16 32 
MTT V2475 8 4 0.5 0.5 16 1 
        Agar V4258 8 4 1 0.5 16 32 
MTT V4258 8 2 0.25 0.5 16 1 
        Agar R 413 8 8 4 0.5 16 32 
MTT R 413 8 8 0.5 0.25 16 0.5 
        Agar R 26 8 32 4 0.5 16 32 
MTT R 26 8 8 0.25 0.5 16 1 
        Agar R 252 8 8 2 0.5 16 32 
MTT R 252 8 4 0.25 1 16 1 
        Agar R 502 8 32 4 0.5 16 32 
MTT R 502 8 8 0.25 0.25 16 0.5 
        Agar R 506 8 32 2 0.5 16 32 
MTT R 506 8 8 0.25 0.5 16 1 
        Agar KZN605 8 32 2 0.5 16 32 
MTT KZN605 8 8 0.25 0.25 16 0.5 



















4.2 Time Kill Experiments  
The isolates used were V4207 (Susceptible), V1435 and V4258 (both MDR-TB), R252 and 
KZN605 (both XDR-TB). H37Rv was used as reference susceptible strain. The time kill 
curves (TKCs) (Figures 1-12) were constructed based on the average numbers of colony 
forming units (cfus) obtained in 6 experiments.The range of values and raw data used to 
construct the TKC for each of the time-points for each of the 6 experiments are given in 
Appendix 6 and Appendix 7. The time kill experiments will be illustrated in two manners. 
  
4.2.1 Time Kill Curves of tested isolates and H37Rv by Anti-TB Drugs  
The results for H37Rv are shown in Figure 1. This strain was killed when exposed to CAP, 
LIN and M&C respectively. This total kill was achieved by CAP on day 14, by M&C on day 
21 and by LIN by day 28. This effect was expected as H37Rv is a susceptible strain. Exposure 
to PAS, resulted in H37Rv steadily decreasing in number of colony forming units (cfu), from 
5.06 Log cfu/mL to 2.15 Log cfu/mL, however it did not kill H37Rv completely during the 
exposure time of 28 days. INH caused a decrease in number of cfus of H37Rv, over the first 3 
days, where a decrease of almost 1.5 log cfu/ml occurred. A small increase in number of cfus 
(0. 43 log cfu/ml) then occurred between day 3 and day 7, this was followed by yet another 
decrease in cfus (0.13 log cfu/ml). From day 14 till day 28, there is a steady increase in the 
number of cfus of H37Rv. H37Rv continued to grow, when it was not exposed to any anti-TB 
agent.  
 
V4207 (Figure 2) is a susceptible clinical isolate, which shows very similar behaviour to that 
of H37Rv, in that exposure to CAP, LIN and M&C resulted in complete kill, at day 7 and day 
14 respectively. However there were 2 differences in its behaviour compared to H37Rv. 
V4207 was eradicated completely by PAS at day 14 and although INH did not kill it 
completely, no regrowth occurred.  
 
V1435 (Figure 3) is a MDR-TB clinical isolate, which was killed by CAP and M&C 
completely at day 21, while exposure to LIN, resulted in complete eradication by day 28. 
Exposure to INH has no effect as shown by an almost identical curve as the drug free control. 









it recovers thereafter and increases by 4.58 log cfu/ml from day 3 till day 28, thus indicates 
resistance to PAS.  
 
V4258 (Figure 4) which is also a MDR-TB isolate behaves very similarly to V1435, in that it 
is also killed when exposed to M&C, CAP, and LIN, at day 7, 14 and 28 respectively and 
INH has no effect. The only difference with V1435 is that it shows a marked decrease of 3.56 
log cfu/ml when exposed to PAS. However it was still not killed completely in the presence of 
PAS over the 28 day observation period.  
 
XDR-TB strain R252 (Figure 5) is only eradicated completely in the presence of CAP and this 
is achieved at day 21.This isolate shows resistance to INH and PAS, where it increases in 
number of cfu by a 2.38 log cfu/ml and 2.16 log cfu/ml respectively from day 0 to day 28. 
When exposed to LIN, it increases in number of cfu (0.52 log cfu/ml) from day 0 to day 3. 
Thereafter it decreases by 0.98 log cfu/ml till day 14. From then till day 28 it shows resistance 
to LIN, and increases by 1.95 log cfu/ml. Exposure to M&C results in a decrease of 1.04 log 
cfu/ml. Although M&C displayed an inhibitory effect to R252, it was not killed completely 
within 28 days. 
 
KZN 605 (Figure 6) is also an XDR-TB strain and showed continuous growth in the presence 
of INH. PAS and LIN are the only anti-TB drugs that kill off KZN 605 completely, at day 21 
and 28 respectively. M&C, also displays inhibition with a decrease in number of cfus from 
day 0 till day 28 (2.13 log cfu/ml). Like with R252, M&C does not kill KZN605 completely 
within the 28 day period.  Exposure to CAP, results in an initial decrease in number of cfu 
(1.33 log cfu/ml) from day 0 till day 14, but thereafter this XDR-TB isolate shows resistance, 











Figure 1: Time kill curve of H37Rv under drug free conditions and when exposed to the 
5 anti-TB drugs. 
 
 
Figure 2: Time kill curve of V4207 under drug free conditions and when exposed to the 



























































Figure 3: Time kill curve of V1435 under drug free conditions and when exposed to the 
5 anti-TB drugs 
 
 
Figure 4: Time kill curve of V4258 under drug free conditions and when exposed to the 































































Figure 6: Time kill curve of KZN 605 under drug free conditions and when exposed to 



























































Fig. 7-11 shows the same results as Fig. 1-6 but displayed in a different manner. In summary, 
INH had a killing effect on only one isolate. CAP killed all except one isolate. PAS inhibited 
all and showed late killing of 4 isolates. One isolate (XDR-TB) was resistant to LIN while all 
others were killed at different rates. Two isolates (both XDR-TB) showed tolerance to M&C 







































































































Figure 10 Time kill curve of the 5 Isolates and H37Rv when exposed to linezolid 
 
 
Figure 11: Time kill curve of the 5 isolates and H37Rv when exposed to meropenem in 


























































4.3 Sequencing Results 
This section describes the mutations that were detected by means of the sequencing 
experiments. The results are shown below in table 11.The sequencing results showed that 
H37Rv and R252 have no mutations in any of the genes investigated. R26, R506 and 
KZN605, are all XDR-TB isolates, and were shown to have the following mutations A1401G, 
A74G, and G2399A in the rrs, tlyA and rrl2 genes respectively. R413, V666, V1435, V2475, 
V4207, V4258, all have mutations A74G and G2399A in the tlyA and rrl2 genes respectively. 
R502 only had mutations A1401G and G2399A in the rrs and rrl2 genes respectively. It was 
not possible to detect mutations for certain genes in specific isolates. This was due to poor 
quality of the DNA that was isolated and sequenced. This is a strange phenomenon, as even 
though the DNA was deemed poor quality, for a specific isolate it was able to detect 
mutations in other genes, coding resistance to other anti-TB drugs i.e V4207, V666, V1435, 































Table 11: Mutations detected in specified Genes of Interest  for 11 Isolates and H37Rv 
Isolate Profile rrs tlyA thyA rrl1 rrl2 
       H37Rv Susceptible None None None None None 
V4207 Susceptible None A74G PQ None G2399A 
       V666 Mono resistant  PQ A74G None None G2399A 
       V1435 MDR  PQ A74G None None G2399A 
V2475 MDR  None A74G None None G2399A 
V4258 MDR  None A74G PQ None G2399A 
       R 413 Pre XDR None A74G None None G2399A 
       R 26 XDR A1401G A74G None None G2399A 
R 252 XDR None None None None None 
R 502 XDR A1401G PQ None None G2399A 
R 506 XDR A1401G A74G None None G2399A 
KZN 605 XDR A1401G A74G None None G2399A 

















CHAPTER 5  
DISCUSSION AND CONCLUSION 
The global rise of MDR and XDR-TB has forced attention to be focused on the search for 
additional drugs to treat patients infected with these drug resistant strains. This search not 
only includes development of novel drugs but also to assess existing drugs that have so far not 
been considered for the treatment of TB, and older anti-TB drugs that were removed from use 
when the current FLDs with high effectivity and low toxicity came into the market. Such 
drugs have to be evaluated by means of in vitro and in vivo testing. In vitro testing includes 
different forms of susceptibility testing while in vivo testing involves testing in animals as 
well as in patients. The work presented here involves the in vitro evaluation of two “old” anti-
TB drugs, PAS and CAP, and two drugs developed for the treatment of infections other than 
TB, LIN and the combination of M&C. Two different DSTs, one agar based and one broth 
based, were used. The time-kill experiment (TKE) was also performed to better understand 
the activity of the drug on the various isolates over a period of time. The results of these tests 
were compared with each other and with the presence of mutations in the genes coding for the 
targets of the drugs tested.  
 
Eleven isolates were used. They were chosen based on their susceptibility profiles established 
by means of the 1% proportion method on Middlebrook 7H10 agar which is routinely used in 
our setting. These isolates included susceptible, INH mono-resistant, MDR-TB, pre XDR-TB 
and XDR-TB isolates (Table 4). This allowed validation of the routine susceptibility test 
method for the drugs investigated. MICs were determined using solid and liquid based DSTs. 
The results were compared with each other and the isolates were then classified as susceptible 
or resistant using the WHO proposed breakpoints for DST on solid and in liquid media, 
shown in Table 10 (WHO, 2009). These results were then correlated with kill over time as 
well as with the presence of known resistance conferring mutations in the genes coding for the 
respective drug targets, to gain an overall understanding of the cause of resistance or 
susceptibility of MTB to the various anti-TB agents.  
When comparing MICs obtained with the agar dilution method with those obtained in 









differences in MIC, the broth MIC was invariably lower than the MIC on the agar medium. 
This confirms observations of others which were reflected in the lower proposed breakpoints 
for resistance in liquid medium (WHO, 2009). A possible explanation for the higher MICs 
obtained in solid as compared to liquid media is that the liquid based media are read after a 
shorter incubation period. The longer incubation time may partially inactivate the drugs, 
resulting in growth at higher concentrations.  
 
Despite the proposed breakpoints for INH (Table 10) (WHO, 2009) being one dilution lower 
in liquid as compared to solid media, the values obtained with both were identical for all 
isolates.The MICs obtained for CAP and LIN revealed that the broth method always yielded a 
lower MIC than the agar dilution. The MICs were generally only one or two dilution factors 
lower than that of the agar method. This is in keeping with the difference in proposed 
breakpoints for CAP. Breakpoints for LIN on solid media have not been proposed (Table 10) 
(WHO, 2009).  
 
Based on the proposed breakpoints, MICs for PAS were expected to be identical with both 
methods. This however, was not the case in the results obtained. Except for one, all isolates 
had significantly higher MIC values with the agar dilution method. Different from the opinion 
of the WHO committee (WHO, 2009), it seems that PAS follows the trend of most anti-TB 
drugs.  
 
As mentioned before, no breakpoints have been proposed for agar MICs for LIN (Table 10). 
However, both tests produced very similar and reproducible results. Most were identical while 
some different by one dilution. Differences in MIC values of one dilution are interpreted as 
being the same. The MIC for all isolates tested against LIN using the agar dilution method is 
0.5µg/ml. This MIC for isolates of varying susceptibilities was also shown in a study by Tato 
et al, 2006. This study, together with our findings implies that the level of resistance of 
various isolates tested, did not influence the MIC obtained for LIN. 
 
The use of meropenem alone displayed results as expected, which was resistance at high 
concentration (8-16ug/ml). These high MIC’s were expected, as meropenem falls under the 









spectrum ß-lactamase (BlaC) which catalyzes the hydrolysis of the ß-lactam ring, thus 
inactivating meropenem (Hugonnet and Blanchard, 2007). The addition of clavulanic acid 
decreased the MICs to 1-2 mg/l. This is the result of inactivation of the ß-lactamase by means 
of an irreversible bond between the enzyme and clavulanic acid. A study by Hugonnet et al., 
in 2009, also compared the effect of M&C on MTB. This study illustrated M&C’s strong 
activity against XDR-TB (Hugonnet et al., 2009). Our study had similar findings and similar 
MIC values to theirs, of not being higher than 1µg/ml.  
 
All experiments were done in triplicate, and sometimes, even more than that. Both methods 
are sensitive to the size of the inoculum and the actual standardisation procedure. As a means 
to reduce errors in this study, the standardisation procedures for both these DSTs methods 
were kept constant. A concern with respect to MIC determination is that TB isolates can be 
composed of various mycobacterial sub-populations, which may have different susceptibility 
patterns. This will therefore affect susceptibility testing, by producing discrepant results. In an 
effort to avoid this, single colonies were grown up for each isolate. Its progeny was then used 
for all the tests in this study.  
 
The agar dilution method only yields results after 3 weeks. The MTT assay however, was able 
to yield results after just 9 days, as at that point there is sufficient growth to allow the 
reduction of the MTT salt to formazan. This resulted in the reagent to change colour. 
However, colour changes from yellow to purple are not always distinct. Therefore, the MTT 
assay was repeated several times. Recent studies made use of a spectrophotometer or a 
colorimeter to circumvent this problem (Raut et al., 2008). The MTT assay is cheaper than the 
agar dilution method and easy to perform and interpret. It must be performed using a young 
culture, which is between 2 to 4 weeks old, as older cultures affect the results adversely 
(Canetti et al., 1969; Raut et al., 2008). This is because the assay requires cells that are 
metabolically active, as these are the only ones which will be able to produce the 
dehydrogenase enzyme, responsible for reducing the tetrazolium dye. Raut et al (2008) 
claimed that when the MTT assay showed an isolate to be resistant to a drug, that is usually 
correct, but if this assay reveals an isolate to be susceptible, then this may not be accurate, and 
should be confirmed with another laboratory test. Our study does not support this. Although 









these isolates changed from susceptible to resistant (Table 9). However, we have to keep in 
mind that only 12 isolates were tested. Great care was taken to avoid cross contamination, 
since the close proximity of the wells easily leads to such an event. One of the measures to 
avoid cross contamination was to cover wells that were already inoculated with the lid. 
Testing of MDR-TB and XDR-TB isolates in a microtitre plate is a laboratory hazard, as it is 
able to generate aerosols easily, and the risks of spills seem higher as it is a liquid based test. 
As a precautionary measure, the lids of the plates were held securely to the plate with elastic 
bands on each side and thereafter heat sealed in a gas permeable bag. As with all handling of 
MTB isolates, the safety rules should be strictly adhered to, in an effort to minimise the 
hazards. 
 
Results from this study suggest that the MTT assay can be used as a rapid screening test to 
confirm DST results. This assay should always be used in conjunction with another 
conventional method, rather than being the sole DST. It proves useful in that it is able to offer 
information on efficacy of various anti-TB agents within 9 days, as opposed to 3-6 weeks 
with the conventional method. Thus this assay would be useful in resource limited settings, 
with high rates of DR-TB, where clinicians require DST information promptly. Results from 
this assay will undoubtly assist with treatment options. As mentioned previously (Section 
3.6.1), since the MTT assay is a DST, the presence of other antibiotics in the media, can alter 
DST results. Thus one must ensure that the TB isolates are always tranferrend into broth that 
is free of PACT or PANTA, when conducting the MTT assay.  
In a routine laboratory, initial culture of MTB isolates is performed on PACT/PANTA 
containing media. This is done to prevent growth of contaminants that may have escaped the 
decontamination process. For DSTs, sub-cuture of the isolates onto PACT/PANTA-free broth 
will be required. However, this is labour intensive and may lead to further delays in the 
generation of DST results.  
 
Since we expected isolates with the same susceptibility pattern to behave similarly, the TKEs 
were performed for two susceptible (including H37Rv), two MDR-TB and two XDR-TB 
isolates. The isolates were inoculated into the broth to which tyloxapol was added to prevent 
clumping. Unlike Tween 80, this is a detergent which has been shown not to influence TKEs 









acids lowering the pH and thus facilitating the killing of MTB (Vandal et al., 2009). Ortalo-
Magne et al in 1996, suggest that Tween 80 may also be involved in stripping the 
glycoprotein capsule of MTB, thus making the bacterium susceptible to acidic conditions. 
Tyloxapol was therefore used in the TKEs in an effort to avoid biased results, where the 
killing of MTB may be enhanced by the actual media properties, rather than the anti-TB 
agents that were being tested.  
 
TheTKE were performed using twice that of the MIC that was obtained when using the agar 
dilution method and MTT assay. Whilst MICs are available for these drugs, it is not known 
how these drugs perform over time in vitro and in vivo against MTB. Twice the MIC was 
chosen as an arbitrary starting point since not much is currently known on this topic, and it is 
preferable to start at a higher MIC for TKE studies than what is needed to kill or inhibit 
growth of an organism. 
 
TKEs can be performed in two manners. In the first method the concentration of the drug is 
decreased over time, mimicking the decrease in concentration during the dose-time interval in 
vivo. The second method uses a constant concentration of the drug. Both measure the decrease 
in number of viable bacteria at different time points during the experiment. Since we did not 
have access to the equipment needed for the first, this study made use of the second method. 
MIC methodology measures growth inhibition irrespective of whether the organisms are 
killed in the process. Minimal bactericidal concentration (MBC) determination following MIC 
provides information on differences in the concentration that inhibits and that which kills. 
TKEs provide information different from MBCs in that it shows kill over time. This requires 
counts of viable bacteria at various time points. The method applied here involves 
subculturing and thereafter peforming counts of the colony forming units (CFUs). This 
method involves sampling of the broth in which the experiment is performed at 6 time points. 
Ten-fold serial dilutions are made and plated out to obtain a subculture with a number of 
colonies that can be counted reliably. The dilution which yields 20-200 colonies is used. 
Trying to count more than 200 colonies results in counting errors while less than 20 colonies 










Time kill curves (TKCs) of INH and the 5 isolates and H37Rv show that INH as expected was 
unable to kill the two MDR-TB and two XDR-TB isolates. It was also unable to kill all cells 
of the susceptible isolate. As described previously, that part of the bacterial population 
survives when exposed to INH resulting in regrowth at a later time point (Colangeli et al., 
2005; Viveiros et al., 2002). This exposure dependant kill pattern for mycobacteria under INH 
therapy has also been reported in in vivo animal studies (Jayaram et al., 2004). The initial 
rapid kill rate followed by a slow kill rate along with the re-growth of bacteria observed in 
this study is remarkably similar to that observed in an in vitro study by Gumbo et al., (2007) 
using M.tuberculosis H37Ra. Similar results were also found in several other in vitro drug 
susceptibility assays. It was hypothesized that the development of drug induced tolerance and 
transient resistance to INH is responsible for the cessation of INH bactericidal activity 
(Viveiros et al., 2002; Wallis et al., 1999). 
 
CAP was able to kill the full population of all isolates except one of the two XDR-TB 
isolates. The kill of one XDR-TB isolate is an unexpected result, as this isolate shares the 
same MIC with the other XDR-TB isolates. This phenomenon needs confirmation using a 
larger sample size. Drug tolerance or latency could also be the cause of the one XDR-TB 
isolate (KZN 605)tocontinue to grow in the presence of CAP.The MTB strain could be in a 
state of reduced metabolic activity, that can involve either replicating sporadically, very 
slowly or not at all (Primm and Franzblau, 2007).The two XDR-TB isolates could have 
behaved differently during the TKE, despite their identical MIC values due to specific needs 
by the specific MTB isolate i.e. nutrition, space, aeration, and the production of toxic 
metabolites (Vadaddy et al., 2010). In vivo studies have shown that MTB is able to shift into a 
non-replicating drug tolerant state, when nutrients are depleted, thus ensureing that the 
organism is able to remain in a dormant state within the host for long periods of time, till 
conditions are favourable for replication (Vadaddy et al., 2010). Perhaps this could have 
occurred with this XDR-TB isolate (KZN 605) in the presence of CAP.  
 
Within the timeframe, PAS killed the full population of both susceptible isolates. It was also 
able to partially kill two other isolates, one being an MDR-TB isolate, and the other an XDR-
TB isolate. No killing was observed with the remaining two of which one was MDR-TB 









has formerly been described as bacteriostatic. This was only confirmed for some of the 
isolates. The unexpected behaviour of the various isolates, with differing susceptibility 
profiles, suggest that their classification of being MDR or XDR isolates, was unable to 
completely and correctly predict their performance over the 28 day period when exposed to 
PAS. Previous research by Odenholt-Tornqvist et al, in 1991, revealed that when MTB is 
exposed to sub-MICs of β-lactams, this results in various adaptive modifications by the 
organism. These modifications include changes in the cell wall structure, altering the 
ribosomal density as well as the formation of filaments. Since the TKE in this study is an in 
vitro one, one is unable to observe if these modifications occurred. Although this unexpected 
behaviour was observed in the presence of PAS, and not the class of β-lactams as described in 
literature, it still remains a possibile theory as to why the remaining MDR and XDR-TB 
isolates behaved so differently to the other isolates of their respective profiles. 
 
LIN killed the full population of 4of the 5 isolates and H37Rv within 28 days. These isolates 
all had MICs in the susceptible range. One XDR-TB isolate (R252), which was also 
susceptible based on the MIC, was not killed. This phenomenon is similar to that which was 
observed when the isolates were exposed to CAP, and can possibly be due to the above 
mentioned reasons as well. An in vitro study by Cremades et al, in 2011, revealed that 
repeated exposure of LIN to MTB, at subinhibitory concentrations, does not result in MTB 
generating resistant mutants.The study also showed that LIN exhibited bactericidal activity 
against susceptible isolates at high concentrations (Cremades et al., 2011). This was also 
shown in our study, as V4207 and H37Rv were both killed at day 14 and day 28 respectively.  
Our study also shows that LIN was also able to exhibit this property to both MDR-TB and 
one XDR-TB isolates, except R252. Another finding by Cremades et al., 2011, is that the 
bactericidal activity of LIN is low against bacteria in a nonreplicating phase, even if these 
strains are susceptible.  
 
The combination of M&C, killed the full population of both susceptible and both MDR-TB 
isolates within 1 to 3 weeks. The two XDR-TB isolates, despite being susceptible based on 










TKEs are useful in elucidating information regarding the effect of a specific concentration of 
the anti-TB drugs tested on each isolate over a period of 28 days to a certain degree. However, 
it may not be a complete reflection of what happens in vivo. There are numerous additional 
factors that contribute to the effect of the drug on the MTB. These include host factors, i.e. the 
additional effect of the immune system on the MTB infection. There are also physiological 
factors that can influence the effect of the anti-TB agent on MTB, such as pH (Vadaddy et al., 
2010). Various interaction such as plasma-protein binding of the anti-TB agents are also 
absent in in vitroTKEs (Vadaddy et al., 2010). An additional factor is that in an in vivo setting 
one is able observe the effect of other drugs on the anti-TB agents that are being tested. This 
drug interaction often occurs since there are many patients who are co-infected with TB and 
HIV, and thus receive treatment for both of these infections.  
Sequencing of the genes coding for the targets of CAP, PAS and LIN showed three mutations, 
two of which (one for CAP and one for LIN) were also found in susceptible isolates. The thyA 
gene, which was thought to code for resistance to PAS (Rengarajan et al., 2004), showed no 
mutations in our study.This was a concerning factor, since the MDR and XDR-TB isolates 
V1435 and R252 respectively, showed resistance to PAS during the TKE, yet showed no 
mutations in this gene. These two isolates continued to increase in CFU, despite them having 
the same MIC as H37Rv and V4207 which were both killed in the presence of PAS. A similar 
finding was made by Mathys et al in 2009 when phenotypic MIC values obtained by the 
BACTEC /Alert and dilution assay were compared to the genotypic sequencing results. They 
had alsoobserved that mutations were not present in the thyA gene, despite the clinical isolates 
displaying resisitance. They then investigated 8 other genes that could confer resistance to 
PAS, but discovered that none of these sites had any mutations. This thus implies that 
mutations at the thyA gene are not necessary to reflect resistance to PAS. This supports our 
findings. Mathys et al, (2009) suggested that this resistance could be dependant on the PAS 
concentration. Perhaps the next step to determine if this is true is to test various 
concentrations of PAS in a TKE, in an effort to determine which concentration is most 
efficient at inhibiting growth of MTB.    
Findings of previous studies suggest that mutations in both the tlyA and the rrs genes confer 
resistance to CAP (Jugheli et al., 2009; Maus et al., 2005a and Maus et al., 2005b). Our 









were mutations in the tlyA gene at the A74G region, for all MDR-TB, pre-XDR-TB, mono-
resistant-TB, one susceptible isolate and 3 out of the 5 XDR-TB isolates that were tested. This 
mutation was not present in the 2 remaining XDR-TB isolate as well as the susceptible control 
strain, H37Rv. This result is conflicting to the MICs that were obtained with both the agar 
dilution and the MTT assay, which implies that all isolates except KZN 605 are susceptible to 
CAP, based on the break point concentration proposed by WHO in 2009 (Table 10).  
According to the TKE, only KZN 605 continued to grow in the presence of CAP. This is 
conflicting, since V4207, V1435 and V4258, which were also tested in the TKE, also 
contained mutations in the tlyA gene, yet they were killed off in the presence of CAP. A 
similar finding was made by Engstrom et al, in 2011. Their study had a much larger sample 
size and also compared MIC values and genotypic sequencing information. It was discovered 
that not all of the mutations in the tlyA gene leads to resistance to capreomycin, and thus tlyA 
can not be used as a sensitive genetic marker (Engstrom et al., 2011). This was due to the fact 
that frameshift or missense mutations at this region of the tlyA gene do not lead to resistance 
to CAP. Perhaps the mutations that were displayed in the tlyA gene of the susceptible and 
MDR-TB isolates, in our study,which were still susceptible to CAP according to the break 
point concentrations by WHO, in 2009 (Table 10), were also these missense mutations. Thus 
this mutation was not a true reflection of resistance to CAP.  Our study also sequenced the rrs 
gene. According to our sequencing results, all the XDR-TB isolates had mutations in A1401G 
region, except R252. This would imply that all isolates are resistant to CAP. This is supported 
by the MICs that were obtained in our study, where all isolates except R252 had an MIC of 32 
µg/ml, which classifies it as resistant to CAP according to the WHO breakpoints (2009) 
(Table 10). The one XDR-TB isolate (R252), which did not have the mutation at the rrs gene, 
also had a lower MIC, making it susceptible to CAP. Thus mutations in the rrs gene, seem to 
be a better and more sensitive marker to CAP resistance than tlyA. This finding is also 
supported by the work of Engstrom et al, (2011).  
 
Sequencing results for LIN revealed no mutations in the rrl1 region. The rrl2 region, 
however, had mutations at the G2399A site in all the isolates tested except H37Rv and one 
(R252) of the 5 XDR-TB isolates. Surprisingly, all isolates had the same MIC value of 









was the only isolate which continued to grow in the presence of LIN, for the entire 28 day 
period. It is unlikey that this mutation at the rrl2 region conferred this resistance to LIN, since 
it was also present in H37Rv, which was killed in the presence of LIN, during the same TKE, 
under the same conditions. It is possible that this mutation, could be a silent mutation, and 
does not affect the isolates resistance to LIN. 
 
The results indicate drug tolerance of MTB for PAS, LIN and M&C. This differs from that 
with INH since INH tolerance is only seen in a subpopulation of the bacterial cells. The 
tolerance that is observed against the non-first line drugs involves the whole population of 
organisms of each tolerant isolate. This is a novel observation. Its clinical importance needs to 
be further investigated.  
 
The tolerance phenomenon was only observed in MDR-TB isolates irrespective of whether 
these had evolved to XDR-TB or not. Due to the small number of isolates tested, this could be 
a chance observation. If this observation is confirmed when the number of isolates are 
increased, then this may reflect an additional mechanism of resistance. The mechanism on 
which this tolerance is based needs to be elucidated. Since the tolerance for the different drugs 
were not observed in the same isolate, more than one mechanism might be involved. 
Perhaps the next step of this TKE is to test different concentrations of each drug at different 
time points, and to test various combinations of drugs, for e.g. it was reported that LIN has a 
synergistic relationship with fluoroquinolones (Diaz et al., 2002). One could perform TKEs 
using various concentrations of two or more drugs to gain better insight of how these agents 
behave synergistically over time. The additional resistance to CAP which was illustrated in 
the results indicates that the XDR-TB strain that circulates in KZN can be classified as a 
TDR-TB strain. It is resistant to INH, RIF, PZA, EMB, ETH, SM, KAN, AMIK and the 
quinolones (Dookie et al., 2012).  
 
According to Olson et al, (2011) at least 3 to 4 new classes of anti-TB drugs are required to 
treat TDR-TB. The ability to develop these new drugs however, is hampered by various 
financial and technical factors. There is a 90 % failure rate from target identification to the 









trials. This entire process will take at least 10 -14 years and often longer, when dealing with 
drugs for TB. The cost to develop just one drug is US $ 1.5 billion, from the discovery to the 
approval step. This cost however does not include the cost for follow up studies that are 
necessary to detect adverse events and side effects of the drug, after it has been launched, nor 
does it cover the manufacturing compliance and drug delivery costs. Although many 
prospective drugs are in their developmental stages, they may only be ready for use in a few 
years’ time.  
 
CONCLUSION  
The agar dilution assay was reproducible for all SLD and TLD anti-TB drugs tested. The 
MTT assay provided MIC results that were reproducible to the agar dilution method for all 
anti-TB drugs except PAS. This illustrates that the MTT assay can be used as an alternate 
method of DST. An additional advantage of this assay is that results can be obtained within 9 
days. This is important to speed up diagnosis and treatment options.TKEs provided insight to 
the rate of kill of the anti-TB drugs tested. It highlighted the phenomenon of drug tolerance 
for some of the MDR and XDR-TB isolates. This was observed when PAS, M&C, LIN were 
unable to kill off the population of these isolates over the 28 day testing period. This was 
unexpected as these isolates fell within the susceptible category based on the MIC results. 
Sequencing was used to resolve discrepancies of the susceptibility patterns that were observed 
using the phenotypic methods of DST. The sequencing results however did not fully resolve 
these discrepancies as mutations that were detected for CAP and LIN, were also present in the 
susceptible isolates. Additionally, one of the XDR-TB isolates resistant to CAP did not have 
any mutations present in the rrs or tlyA gene. Thus indicating other means of DR. This work 
shows that three of the four alternative drugs for the treatment of patients in KZN that are 
infected with the TDR-TB strain are active in vitro. However, LIN and PAS have such serious 
side effects that most patients will not be able to complete a full 2 year course with these 
drugs. In addition, further investigations are needed to establish the role in clinical practice of 
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Solutions used for retrieval of isolate and agar dilution experiment. 
 
1.1 Middlebrook 7H9 Broth (For DST use ) 
Middlebrook 7H9 broth (Becton Dickinson & Company, Difco Laboratories,  
USA)                                                                                                                    4.7g                                                                                                                               
Bacto Casitone (Becton Dickinson & Company, Difco Laboratories,  
USA )                                                                                                                      1g  
Glycerol   (Merck, SA)                                                                                         2ml 
Distilled water                                                                                                   900ml 
OADC (Becton Dickinson and company, USA)                                              100ml                                          
 
The broth powder was weighed out and added to a flask containing the water. 
Bacto casitone and glycerol were added. The contents in the flask was dissolved using a 
magnetic stirrer bar on a magnetic plate. The top of the flask was then covered with foil and 
autoclaved for 15 minutes at 121 °C. The broth was then cooled to room temperature and the 
OADC was added. PACT was not added to the broth when it was used for DST use, as these 
antibiotics may have influenced the results by affecting growth of MTB. 
 
For growth use: PACT was added to the 1 L of broth at the following volumes: 
Polymyxin B (Sigma-Aldrich, USA)                                                    200.000 IU/L  
 Amphotericin B (Sigma-Aldrich, USA),                                                      20mg/L  
 Carbenicillin (Sigma-Aldrich, USA)                                                          100mg/L 
 Trimethoprim (Sigma-Aldrich, USA)                                                           20mg/L 
 
1.2 Middlebrook 7H11 agar 
Middlebrook 7H11 agar (Becton Dickinson & Company, Difco Laboratories,  
USA )                                                                                                                    21g                                                                                                                                









USA )                                                                                                                      1g  
Glycerol   (Merck, SA)                                                                                         5ml 
Distilled water                                                                                                   900ml 
L-asparagine (Sigma- Aldrich, USA)                                                                     5g 
OADC     (Becton Dickinson and company, USA )                                         100ml  
 
Middlebrook powder was weighed out and added to a flask containing the water. The Bacto 
casitone and L asparagine were then weighed out and also added. The glycerol was added to 
the flask. The solution was dissolved using a magnetic stirrer bar. The top of the flask was 
then covered with foil and autoclaved at 121 °C for 15 minutes. 
The flask was taken out and allowed to cool in a water bath before OADC was added. The 
flask was swirled gently and thereafter plates were poured aseptically. 
 
1.3 MTB storage media 
Protease peptone (Becton Dickinson & Company, Difco Laboratories,  
USA)                                                                                                                       4g 
glycerol (Merck, SA)                                                                                          32ml 
Distilled water                                                                                                   400ml 
 
All reagents were added to the 400 ml of water in the flask. This was dissolved with the aid of 
a magnetic stirrer.  
The contents was then autoclaved at 121°C for 15 minutes  
 
1.4 Anti-TB drugs  
1.4.1 Isoniazid (Sigma-Aldrich, USA): 
 A stock solution of 800µg/ml was made in sterile deionised water. This was filter sterilised 
using a Millipore 0.22 µm pore size filter unit (Merck Millipore, SA) and 7 double dilutions 
were performed. This was done to obtain 7 working concentrations: (400µg/ml; 200µg/ml; 
100µg/ml; 50µg/ml; 25µg/ml; 12.5µg/ml; 6.25µg/ml). Therefore when 1 ml of the 7 above 
mentioned concentrations is added to 100ml of Middlebrook 7H10 media to make the agar 
dilutions, then the required concentrations of (4µg/ml; 2µg/ml; 1µg/ml; 0.5µg/ml; 0.25µg/ml; 










1.4.2 Capreomycin in the form of capreomycin sulphate from Streptomyces capreolus  
(Sigma-Aldrich, USA): 
A stock solution of 12800µg/ml was made in sterile deionised water. This was filter sterilised 
using a Millipore 0.22 µm pore size filter unit (Merck Millipore, SA) and 7 double dilutions 
were performed. This was done to obtain 7 working concentrations: (6400µg/ml; 3200µg/ml; 
1600µg/ml; 800µg/ml; 400µg/ml; 200µg/ml; 100µg/ml). Therefore when 1 ml of the 7 above 
mentioned concentrations is added to 100ml of Middlebrook 7H10 media to make the agar 
dilutions, then the required concentrations of (64µg/ml; 32µg/ml; 16µg/ml; 8µg/ml; 4µg/ml; 
2µg/ml; 1µg/ml) was achieved.  
 
1.4.3 Para-aminosalicylic acid in the form of 4-Aminosalicylic acid (Sigma-Aldrich, 
USA):  
A stock solution of 3200µg/ml was made in sterile deionised water. This was filter sterilised 
using a Millipore 0.22 µm pore size filter unit (Merck Millipore, SA) and 7 double dilutions 
were performed. This was done to obtain 7 working concentrations: (1600µg/ml; 800µg/ml; 
400µg/ml; 200µg/ml; 100µg/ml; 50µg/ml; 25µg/ml). Therefore when 1 ml of the 7 above 
mentioned concentrations is added to 100ml of Middlebrook 7H10 media to make the agar 
dilutions, then the required concentrations of (16µg/ml; 8µg/ml; 4µg/ml; 2µg/ml; 1µg/ml; 
0.5µg/ml; 0.25µg/ml) was achieved.  
 
1.4.4 Linezolid in the form of zyvox (Pfizer, SA):  
A stock solution of 1600µg/ml was made in sterile deionised water. This was filter sterilised 
using a Millipore 0.22 µm pore size filter unit (Merck Millipore, SA) and 7 double dilutions 
were performed. This was done to obtain 7 working concentrations: (800µg/ml; 400µg/ml; 
200µg/ml; 100µg/ml; 50µg/ml; 25µg/ml; 12.5µg/ml). Therefore when 1 ml of the 7 above 
mentioned concentrations is added to 100ml of Middlebrook 7H10 media to make the agar 
dilutions, then the required concentrations of (8µg/ml; 4µg/ml; 2µg/ml; 1µg/ml; 0.5µg/ml; 












1.4.5 Meropenem in the form of meronem (AstraZeneca, SA):  
A stock solution of 1600µg/ml was made in sterile deionised water. This was filter sterilised 
using a Millipore 0.22 µm pore size filter unit (Merck Millipore, SA) and 7 double dilutions 
were performed. This was done to obtain 7 working concentrations: (800µg/ml; 400µg/ml; 
200µg/ml; 100µg/ml; 50µg/ml; 25µg/ml; 12.5µg/ml). Therefore when 1 ml of the 7 above 
mentioned concentrations is added to 100ml of Middlebrook 7H10 media to make the agar 
dilutions, then the required concentrations of (8µg/ml; 4µg/ml; 2µg/ml; 1µg/ml; 0.5µg/ml; 
0.25µg/ml; 0.125ug/ml) was achieved.  
 
1.4.6 Clavulanic acid in the form of potassium clavulanate from clavuligerus (Sigma-
Aldrich, USA):  
A stock solution of 1600µg/ml was made in sterile 0.1M phosphate buffer at a pH of 6 
(Appendix 1.5). This was filter sterilised using a Millipore 0.22 µm pore size filter unit 
(Merck Millipore, SA) and only 1 double dilutions was performed. This was done to obtain 1 
working concentration: (800µg/ml). Therefore when 1 ml of the above mentioned 
concentration is added to 100ml of Middlebrook 7H10 media to make the agar dilutions, then 
the required concentration of (8µg/ml) was achieved.  
 
1.5 0.1M Phosphate  buffer  at pH 6 
Potassium dihydrogen orthophosphate (Merck, SA) KH2PO4                         1.36g                             
di-Sodium hydrogen orthophosphate (Merck, SA)  Na2HPO4                        1.42 g 
 
 KH2PO4 ( molar mass 136.09) and Na2HPO4  ( molar mass 141.96) were weighed out and 
added to 80 ml of distilled   water. This solution was adjusted to a pH of 6, and the volume 
increased to 100ml, with water. Aliquots of 10ml were made and were autoclaved at 121 for 
15 minutes. 
 
1.6 Middlebrook 7H10agar plates 
Middlebrook 7H10 agar (Becton Dickinson & Company, Difco Laboratories,  
USA)                                                                                                                     19g                                                                                                                                           
Bacto Casitone     (Becton Dickinson & Company, Difco Laboratories,   









Glycerol   (Merck, SA)                                                                                         5ml 
Distilled water                                                                                                   900ml 
OADC  (Becton Dickinson and company, USA )                                            100ml     
 
Middlebrook powder was weighed out and added to a flask containing the water. The Bacto 
casitone was then weighed out and also added. The glycerol was added to the flask. The 
solution was dissolved using a magnetic stirrer bar. The top of the flask was then covered with 
foil and autoclaved at 121 °C for 15 minutes. 
The flask was taken out and allowed to cool in a water bath before OADC and the anti-TB 
drug (at the required concentration) was added. The flask was swirled gently and thereafter 
plates were poured aseptically. 
 
1.7 Phosphate Buffered Saline  (PBS) (Sigma-Aldrich, USA) 
1 Tablet was dissolved in 200 ml of sterile distilled water.  
The solution was autoclaved at 121° C for 15 minutes. 
 
1.8  0.05 % Tween 80 (Sigma-Aldrich, USA) 
0.05ml Tween 80 was added to 80 ml of sterile distilled water. This was stirred and dissolved. 
If Tween still did not dissolve, the solution could be heated up to 56°C. The entire solution 
was then filter-sterilised using a Millipore 0.22 µm pore size filter unit (Merck Millipore, 
SA). This solution can be stored for up to 2 months at room temperature.  
 
1.9 20% Tween 80 (Sigma-Aldrich, USA) 
20 ml of Tween 80 was added to 80 ml sterile distilled H2O. This was stirred and dissolved. If 
Tween still did not dissolve, the solution could be heated up to 56°C. The entire solution was 
then filter-sterilised using a Millipore 0.22 µm pore size filter unit (Merck Millipore, SA). 
This solution can be stored for up to 2 months at room temperature.  
 
1.10 McFarland No. 1 Standard 
a) 0.5 ml of concentrated H2SO4  (Merck, SA) was added to 49.5 ml of triple distilled water, to 









b) 0.175g of BaCl2.2H2O (Sigma-Aldrich, USA) was added to 10 ml of triple distilled water 
to make a 1 % BaCl2.2H2O solution. 
Thereafter 4.950 ml of 1 % H2SO4 solution was combined with 50 µl of 1 %    BaCl2.2H2O 
solution. The tube containing this McFarland 1 suspension was then stored in foil or away 





































MTT Assay solutions  
 2.1 MTT (3-[4, 5-dimethylthiazol-2-yl]-2, 5- diphenyltetrazolium bromide (5mg/ml) 
(Sigma Aldrich, USA) 
0,1g of the MTT salt was weighed out and added to 20ml PBS of pH 6.8 (Appendix 1.7) 
Three separate tubes of this solution were made. The tubes were vortexed, however if there 
was difficulty with dissolving, then tubes were placed in a water bath of 25°C for about 15-30 
minutes.  
Using a water bath at a higher temperature causes the MTT solution to change colour, and 
thus the tubes have to be monitored regularly. The MTT solution was then filter sterilised 
using a Millipore 0.22 µm pore size filter unit (Merck Millipore, SA) and tubes were covered 
in foil and stored at 4 °C. 
 
2.2 20 % Sodium Dodecyl Sulfate (SDS) (Sigma-Aldrich, USA) 
2g of SDS was weighed and added to 10ml of distilled water. This solution was not vortexed, 
but instead it was inverted and place in a water bath at 30-35°C to help dissolve all the SDS. 
This was then filter sterilised using a Millipore 0.22 µm pore size filter unit (Merck Millipore, 
SA) 
SDS is hazardous and the fine particles are able to disperse easily. This should be weighed out 
and made in a fume hood or while wearing a safety face mask. 
 
2.3 50 % aqueous N, N Dimethylformamide (DMF) (Sigma-Aldrich, USA)  
Equal volumes of DMF and distilled water were combined to make a 50 % solution i.e. 20 ml 
of DMF and 20 ml of distilled water. 
This was stored in an amber bottle or in a bottle covered with foil and stored away from direct 
light.  
 
2.4 1: 1 vol/vol SDS-DMF solution (of the 20% SDS and 50 % DMF solution) 
Equal volumes of each of the solutions were combined i.e. 30 ml of the 20 % SDS solution to 









SDS was added to the DMF, instead of vice versa, as this prevents a white precipitate from 
forming. This SDS-DMF solution was stored in a amber bottle or bottle covered in foil and 






































Appendix 3  
Time kill experiment solutions  
3.1 20 % Tyloxapol (Sigma-Aldrich, USA) 
2ml of tyloxapol was added to 8 ml of sterile distilled water.  
This was then sterilised by filtering through Millipore 0.22 µm pore size filter unit (Merck 
Millipore, SA). 
 
3.2 PBS and 20 % Tyloxapol (Both : Sigma-Aldrich, USA) 
625µl of this solution was added to 250 ml of PBS (Appendix 1.7) and was used to make 900 
µl aliquots for the dilution blanks for the TKE.  






























Appendix 4  
DNA isolation and sequencing solutions 
4.1 10x TE Buffer  
Trizma base (Sigma-Aldrich, USA) 1.21g  
EDTA (Sigma-Aldrich, USA) 0.37g 
 
The trizma base was weighed out and dissolved in 80ml of distilled water. It was the adjusted 
to a pH of 8 using concentrated HCl (Merck).The EDTA was then added and dissolved. The 
final pH of the entire suspension was checked and adjusted to a final volume of 100ml. This 
was then autoclaved at 121°C for 15 minutes.  
This was then used to make a 1x TE Buffer. 
 
1x TE Buffer  
10ml of 10x TE Buffer was diluted into 90ml of triple distilled water. This solution was stored 
at room temperature.  
 
4.2 Lysozyme (10mg/ml) (Sigma-Aldrich, USA)  
1ml of distilled water was added to 10mg of lysozyme powder. This solution was stored at 
4°C until use. 
 
4.3 Proteinase K (10mg/ml) (Roche Diagnostics)  
10ml of distilled water was added to 100mg of proteinase K powder. This solution was  store 
at 4°C until use.  
 
4.4 10% Sodium Dodecyl Sulfate (SDS) (Sigma-Aldrich, USA)  
10g of SDS powder weighed and dissolve in 100ml of distilled water. Refer to Appendix 2.2 









4.5 5M Sodium Chloride (NaCl) (Sigma-Aldrich, USA)  
14.6 g of NaCl powder was weighed out and dissolved in 50ml of distilled water. This 
solution was then autoclaved at 121°C for 15 minutes.  
 
 
4.6 CTAB-NaCl Solution 
NaCl (Sigma-Aldrich, USA) 4.1g  
CTAB (Sigma-Aldrich, USA) 10g  
 
The above powders were weighed out and dissolved in 100ml of distilled water. The solution 
was heated to 65°C until powders are completely dissolved.  
 
 
4.7 Chloroform: Isoamyl alcohol (24:1) (Sigma-Aldrich, USA) 
1ml of isoamyl alcohol (Sigma-Aldrich, USA) was added to 24ml of chloroform (Sigma-
Aldrich, USA).  
 
 
4.8 70% ethanol 









4.9 1% agarose gel (140ml)   
Agarose powder (Lonza, USA)                                                                           1.4g  
1x TBE buffer                                                                                                   140ml  
Ethidium bromide                                                                                              140μl  
 
The agarose powder was weighed and added to a flask containing 1x TBE buffer (Appendix 
4.10). The mixture was heated in a microwave to dissolve the powder. It was then allowed to 
cool and ethidium bromide was added.  
 
4.10 10xTBE Buffer 
Trizma base (Sigma-Aldrich, USA)                                                                   108g  
Boric acid (Sigma-Aldrich, USA)                                                                        55g  
EDTA (Sigma-Aldrich, USA)                                                                             9.3g   
 
The above reagents were weighed out and dissolved in 1000ml of distilled water. 
  
1x TBE  
100ml of 10x TBE was added to 900ml of distilled water.  
 
4.11 Ethidium Bromide (5μg/ml)  
10mg of ethidium bromide powder was weighed out and dissolved in 20ml of distilled water. 
The bottle was then wrapped in foil and stored at 4°C. Great care must be taken when 










4.12 Sample loading dye  
1% Double dye  
Bromphenol Blue (Sigma-Aldrich, USA)                                                              1g  
Xylene cyanole (Sigma-Aldrich, USA)                                                                  1g  
 
The above powders were weighed out and dissolved in 100ml of distilled water.  
 
50 ml of loading dye was then prepared from the above 1% Double Dye (DD) stock solution 
 
10x TBE                                                                                                               5 ml  
Glycerol (Merck, SA)                                                                                        25 ml  
1% Double dye                                                                                                    5 ml  
The required amounts of the above mentioned reagents were added to 15ml of distilled water. 
This was then dissolved properly and stored at 4°C until it was used for gel electrophoresis. 
 
4.13 3M Sodium Acetate NaOAc (Sigma Aldrich, USA) at a pH of 5.2 
40.8 g of NaOAc was weighed out and dissolved in 70 ml of deionised water.  
Glacial acetic acid was used to obtain a pH of 5.2. The volume was increased to a final 




















Formula for calculations performed to construct a TKC from raw data  
Time kill curves were constructed by adding the colony counts of each triplicate set (A, B, C). 
These sets were also done in duplicate (A1, A2, B1, B2, C1, C2) 
Therefore for each of the 6 time points (Day 0, Day 3, Day 7, Day 14, Day 21, and Day 28) an 
average of the total colony counts were calculated. This was divided by 20 (as only 50µl out 
of the total 1000µl was inoculated to do the colony counts) and multiplied by the dilution 
factor that gave a countable number of colonies (10, 100, 1000, 10000, 100000). This value 
was then converted to a log value. 
A final average log value for the Log A, Log B and Log C was used for each isolate for the 
specific drugs   
 
       
Log              (Sum of colony count A1*+A2*)     X Dilution Factor  
                                               20 
 
 
Note * : the A1* and A2* values in the above formula were substituted by B1 and B2, C1 and 
C2 values, to get a total average log value of the entire colony count data for the triplicate 
experiment at each time point. 
This final average value was used to construct the time kill curves (Figure 1-Figure 11).  
 
Refer to the example (Below) of how the raw data was used to calculate the log values which 


















Raw data used to calculate log values for the time kill curves 
 
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 34100 2130000 146000000 174000000 192000000 219000000
INH 69000 0 6300 2170000 2310000 1170000
PAS 191000 126000 3270000 2950000 3310000 2750000
CAP 118000 0 1100 0 0 0
LIN 73000 32100 0 0 0 0
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 4.53 6.33 8.16 8.24 8.28 8.34
INH 4.84 0 3.8 6.34 6.36 6.07
PAS 5.28 5.1 6.51 6.47 6.52 6.44
CAP 5.07 0 3.04 0 0 0
LIN 4.86 4.51 0 0 0 0
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 51000 1630000 114000000 31100000 212000000 295000000
INH 131000 1480000 12800 0 0 3490000
PAS 146000 84000 145000 0 0 0
CAP 56000 700 800 0 0 0
LIN 100000 0 0 0 0 0
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 4.71 6.21 8.06 7.5 8.33 8.47
INH 5.12 6.17 4.11 0 0 6.54
PAS 5.16 4.92 5.16 0 0 0
CAP 4.75 2.85 2.9 0 0 0
LIN 5 0 0 0 0 0
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 32400 2900000 139000000 13900000 188000000 261000000
INH 56000 1200 17400 1790000 55000000 2900000
PAS 56000 150000 265000 25600 0 0
CAP 99000 0 500 0 0 0
LIN 174000 258000 121000 31000 19900 0
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 4.51 6.46 8.14 7.14 8.27 8.42
INH 4.75 3.08 4.24 6.25 7.74 6.46
PAS 4.75 5.18 5.42 4.41 0 0
CAP 5 0 2.7 0 0 0
LIN 5.24 5.41 5.08 4.49 4.3 0
Log Values of H37Rv A1 and A2 mean colony count values for TKE 1
H37Rv A1 and A2 Mean colony count values for TKE 1
H37Rv B1 and B2 Mean colony count values for TKE 1
Log Values of H37Rv B1 and B2 mean colony count values for TKE 1
H37Rv C1 and C2 Mean colony count values for TKE 1













Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 4.58 6.33 8.12 7.63 8.29 8.41
INH 4.9 3.08 4.05 4.2 4.7 6.36
PAS 5.06 5.07 5.7 3.63 2.17 2.15
CAP 4.94 0.95 2.88 0 0 0
LIN 5.03 3.31 1.69 1.5 1.43 0
Average of H37Rv log values for A1,A2, B1, B2, C1 and C2 for TKE 1
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 24000 3230000 126000000 306000000 500000000 500000000
INH 158000 16400 13100 4800 30500 3010000
M&C 29400 20300 11700 2700 0 0
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 4.38 6.51 8.1 8.49 8.7 8.7
INH 5.2 4.21 4.12 3.68 4.48 6.48
M&C 4.47 4.31 4.07 3.43 0 0
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 24600 2690000 99000000 269000000 500000000 500000000
INH 146000 9600 6500 2600 25700 2070000
M&C 37000 19900 10000 1700 0 0
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 4.39 6.43 8 8.43 8.7 8.7
INH 5.16 3.98 3.81 3.41 4.41 6.32
M&C 4.57 4.3 4 3.23 0 0
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 28700 23400000 149000000 332000000 500000000 500000000
INH 221000 11400 9700 3900 28300 3120000
M&C 32400 22700 12700 2300 0 0
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 4.46 7.37 8.17 8.52 8.7 8.7
INH 5.34 4.06 3.99 3.59 4.45 6.49
M&C 4.51 4.36 4.1 3.36 0 0
H37Rv C1 and C2 Mean colony count values for TKE 3
Log Values of H37Rv C1 and C2 mean colony count values for TKE 3
H37Rv A1 and A2 Mean colony count values for TKE 3
Log Values of H37Rv A1 and A2 mean colony count values for TKE 3
H37Rv B1 and B2 Mean colony count values for TKE 3
Log Values of H37Rv B1 and B2 mean colony count values for TKE 3
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 4.41 6.77 8.09 8.48 8.7 8.7
INH 5.23 4.08 3.97 3.56 4.45 6.43
M&C 4.52 4.32 4.06 3.34 0 0









Final log values used to construct the time kill curves for H37Rv 
 






Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 4.5 6.55 8.11 8.05 8.5 8.56
INH 5.07 3.58 4.01 3.88 4.57 6.39
PAS 5.06 5.07 5.7 3.63 2.17 2.15
CAP 4.94 0.95 2.88 0 0 0
LIN 5.03 3.31 1.69 1.5 1.43 0
M&C 4.52 4.32 4.06 3.34 0 0
Total Average of Log values for H37Rv A1, A2, B1, B2, C1, C2 for TKE 1 & TKE 3
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 85000 258000 640000 1110000 1550000 1990000
INH 104000 0 0 0 0 0
PAS 112000 143000 14700 0 0 0
CAP 88000 5000 0 0 0 0
LIN 56000 143000 0 0 0 0
V4207 A1 and A2 Mean colony count values for TKE 1
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 4.93 5.41 5.81 6.05 6.19 6.3
INH 5.02 0 0 0 0 0
PAS 5.05 5.16 4.17 0 0 0
CAP 4.94 3.7 0 0 0 0
LIN 4.75 5.16 0 0 0 0
Log Values of V4207 A1 and A2 mean colony count values for TKE 1
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 57000 277000 1010000 1620000 2110000 2760000
INH 147000 225000 0 0 0 0
PAS 134000 245000 900 0 0 0
CAP 103000 500 0 0 0 0
LIN 89000 253000 11500 0 0 0
V4207 B1 and B2 Mean colony count values for TKE 1
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 4.76 5.44 6 6.21 6.32 6.44
INH 5.17 5.35 0 0 0 0
PAS 5.13 5.39 2.95 0 0 0
CAP 5.01 2.7 0 0 0 0
LIN 4.95 5.4 4.06 0 0 0
Log Values of V4207 B1 and B2 mean colony count values for TKE 1
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 50000 153000 380000 540000 920000 1260000
INH 318000 52000 0 0 0 0
PAS 57000 299000 900 0 0 0
CAP 134000 4000 0 0 0 0
LIN 68000 8200 239000 0 0 0



















Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 4.7 5.18 5.58 5.73 5.96 6.1
INH 5.5 4.72 0 0 0 0
PAS 4.76 5.48 2.95 0 0 0
CAP 5.13 3.6 0 0 0 0
LIN 4.83 3.91 5.38 0 0 0
Log Values of V4207 C1 and C2 mean colony count values for TKE 1
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 4.8 5.34 5.8 6 6.16 6.28
INH 5.23 3.36 0 0 0 0
PAS 4.98 5.34 3.36 0 0 0
CAP 5.03 3.33 0 0 0 0
LIN 4.84 4.82 3.15 0 0 0
Average of V4207 log values for A1,A2, B1, B2, C1 and C2 for TKE 1
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 1730000 24300000 178000000 353000000 700000000 700000000
INH 382000 315000 28000 14900 5300 1900
M&C 78000 24100 11400 0 0 0
V4207 A1 and A2 Mean colony count values for TKE 3
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 6.24 7.39 8.25 8.55 8.85 8.85
INH 5.58 5.5 4.45 4.17 3.72 3.28
M&C 4.89 4.38 4.06 0 0 0
Log Values of V4207 A1 and A2 mean colony count values for TKE 3
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 1700000 20500000 160000000 357000000 700000000 700000000
INH 336000 32800 25600 10800 2100 400
M&C 116000 27500 17200 0 0 0
V4207 B1 and B2 Mean colony count values for TKE 3
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 6.23 7.31 8.2 8.55 8.85 8.85
INH 5.53 4.52 4.41 4.03 3.32 2.6
M&C 5.06 4.44 4.24 0 0 0
Log Values of V4207 B1 and B2 mean colony count values for TKE 3
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 1730000 25900000 180000000 308000000 700000000 700000000
INH 3180000 326000 29700 15700 5400 2500
M&C 146000 25300 15600 0 0 0
V4207 C1 and C2 Mean colony count values for TKE 3
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 6.24 7.41 8.26 8.49 8.85 8.85
INH 6.5 5.51 4.47 4.2 3.73 3.4
M&C 5.16 4.4 4.19 0 0 0










Final log values used to construct Time kill curves for V4207 
 
 





Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 6.24 7.37 8.24 8.53 8.85 8.85
INH 5.87 5.18 4.44 4.13 3.59 3.09
M&C 5.04 4.41 4.16 0 0 0
Average of V4207 log values for A1,A2, B1, B2, C1 and C2 for TKE 3
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 5.52 6.36 7.02 7.26 7.5 7.57
INH 5.55 4.27 2.22 2.07 1.8 1.55
PAS 4.98 5.34 3.36 0 0 0
CAP 5.03 3.33 0 0 0 0
LIN 4.84 4.82 3.15 0 0 0
M&C 5.04 4.41 4.16 0 0 0
Total Average of Log values for V4207 A1, A2, B1, B2, C1, C2 for TKE 1 and TKE 3
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 1810000 16800000 19900000 11700000 400000000 400000000
INH 2470000 400000000 400000000 400000000 400000000 600000000
PAS 370000 2760000 419000 400000 0 0
CAP 7100000 2130000 510000 302000 192000 2760000
LIN 880000 300000 940000 0 0 0
KZN 605 A1 and A2 Mean colony count values for TKE 1
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 6.26 7.23 7.3 7.07 8.6 8.6
INH 6.39 8.6 8.6 8.6 8.6 8.78
PAS 5.57 6.44 5.62 5.6 0 0
CAP 6.85 6.33 5.71 5.48 5.28 6.44
LIN 5.94 5.48 5.97 0 0 0
Log Values of KZN 605 A1 and A2 mean colony count values for TKE 1
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 2370000 18800000 13500000 400000000 400000000 600000000
INH 1240000 400000000 400000000 400000000 400000000 600000000
PAS 332000 1710000 1480000 400000 0 0
CAP 1730000 2410000 640000 293000 236000 12500000
LIN 1450000 3100000 82000 4300 0 0
KZN 605 B1 and B2 Mean colony count values for TKE 1
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 6.37 7.27 7.13 8.6 8.6 8.78
INH 6.09 8.6 8.6 8.6 8.6 8.78
PAS 5.52 6.23 6.17 5.6 0 0
CAP 6.24 6.38 5.81 5.47 5.37 7.1
LIN 6.16 6.49 4.91 3.63 0 0

















Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 1740000 288000000 29800000 400000000 400000000 800000000
INH 1850000 400000000 400000000 400000000 400000000 600000000
PAS 2130000 1510000 1480000 400000 0 0
CAP 1330000 2960000 590000 18100 82000 2720000
LIN 2000000 2920000 322000 37700 14900 0
KZN 605 C1 and C2 Mean colony count values for TKE 1
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 6.24 8.46 7.47 8.6 8.6 8.9
INH 6.27 8.6 8.6 8.6 8.6 8.78
PAS 6.33 6.18 6.17 5.6 0 0
CAP 6.1 6.47 5.77 4.26 4.91 6.43
LIN 6.3 6.47 5.51 4.58 4.17 0
Log Values of KZN 605 C1 and C2 mean colony count values for TKE 1
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 6.29 7.65 7.3 8.09 8.6 8.76
INH 6.25 8.6 8.6 8.6 8.6 8.78
PAS 5.81 6.28 5.99 5.6 0 0
CAP 6.4 6.39 5.76 5.07 5.19 6.66
LIN 6.13 6.15 5.46 2.74 1.39 0
Average of KZN 605 log values for A1,A2, B1, B2, C1 and C2 for TKE 1
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 2380000 16100000 226000000 500000000 700000000 700000000
INH 1790000 374000 3590000 28800000 500000000 500000000
M&C 364000 25100 22000 16600 9200 3600
KZN 605 A1 and A2 Mean colony count values for TKE 3
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 6.38 7.21 8.35 8.7 8.85 8.85
INH 6.25 5.57 6.56 7.46 8.7 8.7
M&C 5.56 4.4 4.34 4.22 3.96 3.56
Log Values of KZN 605 A1 and A2 mean colony count values for TKE 3
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 2020000 14200000 190000000 500000000 700000000 700000000
INH 1830000 343000 3710000 31700000 500000000 500000000
M&C 359000 29700 22900 14900 6300 2600
KZN 605 B1 and B2 Mean colony count values for TKE 3
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 6.31 7.15 8.28 8.7 8.85 8.85
INH 6.26 5.54 6.57 7.5 8.7 8.7
M&C 5.55 4.47 4.36 4.17 3.8 3.41
Log Values of KZN 605 B1 and B2 mean colony count values for TKE 3
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 2450000 13500000 232000000 500000000 700000000 700000000
INH 360000 2110000 3500000 31500000 500000000 500000000
M&C 335000 31300 22300 15700 8600 2000











Final log values used to construct time kill curves for KZN 605 
  
Raw data used to calculate log values for the R252 time kill curves 
 
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 6.39 7.13 8.37 8.7 8.85 8.85
INH 5.56 6.32 6.54 7.5 8.7 8.7
M&C 5.53 4.5 4.35 4.2 3.93 3.3
Log Values of KZN 605 C1 and C2 mean colony count values for TKE 3
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 6.36 7.16 8.33 8.7 8.85 8.85
INH 6.02 5.81 6.56 7.49 8.7 8.7
M&C 5.55 4.46 4.35 4.2 3.9 3.42
Average of KZN 605 log values for A1,A2, B1, B2, C1 and C2 for TKE 3
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 6.33 7.41 7.82 8.4 8.73 8.81
INH 6.14 7.21 7.58 8.04 8.65 8.74
PAS 5.81 6.28 5.99 5.6 0 0
CAP 6.4 6.39 5.76 5.07 5.19 6.66
LIN 6.13 6.15 5.46 2.74 1.39 0
M&C 5.55 4.46 4.35 4.2 3.9 3.42
Total Average of Log values for KZN605 A1, A2, B1, B2, C1, C2 for TKE 1 &TKE 3
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 59000 1390000 2170000 4500000 28100000 35500000
INH 21100 0 3400 460000 31700 240000
PAS 36300 40000 1670000 3010000 2890000 11600000
CAP 86000 0 0 0 0 0
LIN 49000 246000 50000 16800 352000 1160000
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 4.77 6.14 6.34 6.65 7.45 7.55
INH 4.32 0 3.53 5.66 4.5 5.38
PAS 4.56 4.6 6.22 6.48 6.46 7.06
CAP 4.93 0 0 0 0 0
LIN 4.69 5.39 4.7 4.23 5.55 6.06
R 252 A1 and A2 Mean colony count values for TKE 2














Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 46000 3250000 3520000 19300000 31000000 35600000
INH 28700 2600 2400 153000 15500 99000
PAS 37000 40000 1350000 3090000 2110000 9300000
CAP 154000 5300 500 0 0 0
LIN 54000 228000 32700 19600 1520000 3370000
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 4.66 6.51 6.55 7.29 7.49 7.55
INH 4.46 3.41 3.38 5.18 4.19 5
PAS 4.57 4.6 6.13 6.49 6.32 6.97
CAP 5.19 3.72 2.7 0 0 0
LIN 4.73 5.36 4.51 4.29 6.18 6.53
R 252 B1 and B2 Mean colony count values for TKE 2
Log Values of R 252 B1 and B2 mean colony count values for TKE 2
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 50000 760000 860000 2370000 23800000 27900000
INH 33700 4700 100 253000 1880000 940000
PAS 205000 274000 1010000 3760000 2620000 7400000
CAP 162000 8900 500 100 0 0
LIN 52000 86000 23200 17000 1700000 1010000
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 4.7 5.88 5.93 6.37 7.38 7.45
INH 4.53 3.67 2 5.4 6.27 5.97
PAS 5.31 5.44 6 6.58 6.42 6.87
CAP 5.21 3.95 2.7 2 0 0
LIN 4.72 4.93 4.37 4.23 6.23 6
R 252 C1 and C2 Mean colony count values for TKE 2
Log Values of R 252 C1 and C2 mean colony count values for TKE 2
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 4.71 6.18 6.27 6.77 7.44 7.52
INH 4.44 2.36 2.97 5.41 4.99 5.45
PAS 4.81 4.88 6.12 6.52 6.4 6.97
CAP 5.11 2.56 1.8 0.67 0 0
LIN 4.71 5.23 4.53 4.25 5.99 6.2
Average of R252 log values for A1,A2, B1, B2, C1 and C2 for TKE 2
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 169000 2400000 212000000 421000000 500000000 700000000
INH 33300 29800 279000 355000 22100000 365000000
M&C 112000 30000 15300 12600 7000 4400
R 252 A1 and A2 Mean colony count values for TKE 3
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 5.23 6.38 8.33 8.62 8.7 8.85
INH 4.52 4.47 5.45 5.55 7.34 8.56
M&C 5.05 4.48 4.18 4.1 3.85 3.64














Final log values used to construct time kill curves for R 252 
 
Raw data used to calculate log values for the V4258 time kill curves 
 
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 237000 2700000 240000000 433000000 500000000 700000000
INH 146000 26100 262000 376000 22100000 270000000
M&C 35100 30400 17000 12300 7000 4000
R 252 B1 and B2 Mean colony count values for TKE 3
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 5.37 6.43 8.38 8.64 8.7 8.85
INH 5.16 4.42 5.42 5.58 7.34 8.43
M&C 4.54 4.48 4.23 4.09 3.85 3.6
Log Values of R 252 B1 and B2 mean colony count values for TKE 3
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 234000 2460000 242000000 500000000 500000000 700000000
INH 32200 22900 311000 315000 3770000 254000000
M&C 37700 24700 21700 16200 10100 6500
R 252 C1 and C2 Mean colony count values for TKE 3
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 5.37 6.39 8.38 8.7 8.7 8.85
INH 4.51 4.36 5.49 5.5 6.58 8.4
M&C 4.58 4.39 4.34 4.21 4 3.81
Log Values of R 252 C1 and C2 mean colony count values for TKE 3
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 5.32 6.4 8.36 8.65 8.7 8.85
INH 4.73 4.42 5.45 5.54 7.09 8.46
M&C 4.73 4.45 4.25 4.13 3.9 3.68
Average of R252 log values for A1,A2, B1, B2, C1 and C2 for TKE 3
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 5.02 6.29 7.32 7.71 8.07 8.18
INH 4.58 3.39 4.21 5.48 6.04 6.96
PAS 4.81 4.88 6.12 6.52 6.4 6.97
CAP 5.11 2.56 1.8 0.67 0 0
LIN 4.71 5.23 4.53 4.25 5.99 6.2
M&C 4.72 4.45 4.25 4.133 3.9 3.68
Total Average of Log values for R 252 A1, A2, B1, B2, C1, C2 for TKE 2 &TKE 3
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 195000 382000 20300000 11800000 21400000 76000000
INH 147000 0 3800 215000 1850000 14400000
PAS 206000 137000 144000 330000 219000 0
CAP 75000 10600 200 0 0 0
LIN 73000 255000 298000 11500 600 0













Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 5.29 5.58 7.31 7.07 7.33 7.88
INH 5.17 0 3.58 5.33 6.27 7.16
PAS 5.31 5.14 5.16 5.52 5.34 0
CAP 4.88 4.03 2.3 0 0 0
LIN 4.86 5.41 5.47 4.06 2.78 0
Log Values of V4258 A1 and A2 mean colony count values for TKE 2
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 149000 220000 15100000 102000000 24000000 58000000
INH 59000 1200 800 157000 97000 12300000
PAS 137000 134000 40000 180000 250000 0
CAP 78000 12700 0 0 0 0
LIN 302000 650000 238000 10300 900 0
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 5.17 5.34 7.18 8.01 7.38 7.76
INH 4.77 3.08 2.9 5.2 4.99 7.09
PAS 5.12 5.13 4.6 5.26 5.4 0
CAP 4.89 4.1 0 0 0 0
LIN 5.48 5.81 5.38 4.01 2.95 0
V4258  B1 and B2 Mean colony count values for TKE 2
Log Values of V4258 B1 and B2 mean colony count values for TKE 2
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 240000 810000 21100000 164000000 33800000 31200000
INH 217000 1200 700 293000 3310000 14000000
PAS 92000 144000 21000 185000 87000 50000
CAP 41000 12700 600 0 0 0
LIN 89000 700000 237000 19500 0 0
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 5.38 5.91 7.32 8.21 7.53 7.49
INH 5.34 3.08 2.85 5.47 6.52 7.15
PAS 4.96 5.16 4.32 5.27 4.94 4.7
CAP 4.61 4.1 2.78 0 0 0
LIN 4.95 5.85 5.37 4.29 0 0
V4258  C1 and C2 Mean colony count values for TKE 2
Log Values of V4258 C1 and C2 mean colony count values for TKE 2
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 5.28 5.61 7.27 7.76 7.41 7.71
INH 5.09 2.05 3.11 5.33 5.93 7.13
PAS 5.13 5.14 4.69 5.35 5.23 1.57
CAP 4.79 4.08 1.69 0 0 0
LIN 5.1 5.69 5.41 4.12 1.91 0














Final log values used to construct time kill curves for V4258 
 
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 248000 2120000 26500000 336000000 500000000 500000000
INH 199000 305000 2990000 114000000 351000000 500000000
M&C 162000 6700 0 0 0 0
V4258 A1 and A2 Mean colony count values for TKE 3
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 5.39 6.33 7.42 8.53 8.7 8.7
INH 5.3 5.48 6.48 8.1 8.55 8.7
M&C 5.21 3.83 0 0 0 0
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 237000 1880000 21800000 270000000 500000000 500000000
INH 182000 172000 3200000 130000000 430000000 500000000
M&C 238000 5700 0 0 0 0
Log Values of V4258 A1 and A2 mean colony count values for TKE 3
V4258 B1 and B2 Mean colony count values for TKE 3
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 5.37 6.27 7.34 8.43 8.7 8.7
INH 5.26 5.24 6.51 8.11 8.63 8.7
M&C 5.38 3.76 0 0 0 0
Log Values of V4258 B1 and B2 mean colony count values for TKE 3
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 324000 2660000 29000000 332000000 500000000 500000000
INH 224000 175000 3030000 62000000 222000000 500000000
M&C 141000 6700 0 0 0 0
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 5.51 6.42 7.46 8.52 8.7 8.7
INH 5.35 5.24 6.48 7.8 8.35 8.7
M&C 5.15 3.83 0 0 0 0
Log Values of V4258 C1 and C2 mean colony count values for TKE 3
V4258 C1 and C2 Mean colony count values for TKE 3
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 5.42 6.34 7.41 8.49 8.7 8.7
INH 5.3 5.32 6.49 8 8.51 8.7
M&C 5.25 3.81 0 0 0 0
Average of V4258 log values for A1,A2, B1, B2, C1 and C2 for TKE 3
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 5.35 5.98 7.34 8.13 8.06 8.21
INH 5.2 3.69 4.8 6.67 7.22 7.92
PAS 5.13 5.14 4.69 5.35 5.23 1.57
CAP 4.79 4.08 1.69 0 0 0
LIN 5.1 5.69 5.41 4.12 1.91 0
M&C 5.25 3.81 0 0 0 0













Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 660000 2600000 3420000 17700000 26000000 16200000
INH 280000 322000 94000 295000 3010000 36000
PAS 145000 0 282000 278000 2030000 3220000
CAP 570000 4400 600 500 0 0
LIN 227000 40000 20700 15500 1800 0
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 5.82 6.41 6.53 7.25 7.41 7.21
INH 5.45 5.51 4.97 5.47 6.48 4.56
PAS 5.16 0 5.45 5.44 6.31 6.51
CAP 5.76 3.64 2.78 2.7 0 0
LIN 5.36 4.6 4.32 4.19 3.26 0
V 1435  A1 and A2 Mean colony count values for TKE 2
Log Values of V 1435 A1 and A2 mean colony count values for TKE 2
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 750000 338000 9400000 17800000 14300000 152000000
INH 347000 21000 34300 171000 1920000 1920000
PAS 182000 0 162000 2090000 1430000 3350000
CAP 181000 0 0 0 0 0
LIN 96000 262000 37100 4500 300 0
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 5.88 5.53 6.97 7.25 7.16 8.18
INH 5.54 4.32 4.53 5.23 6.28 6.28
PAS 5.26 0 5.21 6.32 6.16 6.53
CAP 5.26 0 0 0 0 0
LIN 4.98 5.42 4.57 3.65 2.48 0
V 1435  B1 and B2 Mean colony count values for TKE 2
Log Values of V 1435 B1 and B2 mean colony count values for TKE 2
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 311000 2100000 3610000 14400000 3550000 35200000
INH 100000 3120000 224000 13600000 14300000 1910000
PAS 255000 309000 107000 2250000 1830000 1560000
CAP 600000 7700 0 0 0 0
LIN 540000 860000 59000 1600 0 0
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 5.49 6.32 6.56 7.16 6.55 7.55
INH 5 6.49 5.35 7.13 7.16 6.28
PAS 5.41 5.49 5.03 6.35 6.26 6.19
CAP 5.78 3.89 0 0 0 0
LIN 5.73 5.93 4.77 3.2 0 0
V 1435  C1 and C2 Mean colony count values for TKE 2















Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 5.73 6.09 6.69 7.22 7.04 7.65
INH 5.33 5.44 4.95 5.94 6.64 5.71
PAS 5.28 1.83 5.23 6.04 6.24 6.41
CAP 5.6 2.51 0.93 0.9 0 0
LIN 5.36 5.32 4.55 3.68 1.91 0
Average of V1435 log values for A1,A2, B1, B2, C1 and C2 for TKE 2
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 311000 3050000 230000000 416000000 700000000 700000000
INH 363000 276000 2570000 3440000 190000000 341000000
M&C 142000 23600 16200 2200 0 0
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 5.49 6.48 8.36 8.7 8.85 8.85
INH 5.56 5.44 6.41 6.54 8.28 8.53
M&C 5.15 4.37 4.21 3.34 0 0
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 2030000 35900000 317000000 500000000 700000000 700000000
INH 1520000 322000 2860000 3560000 28600000 247000000
M&C 155000 33500 11900 0 0 0
V1435 A1 and A2 Mean colony count values for TKE 3
Log Values of V1435 A1 and A2 mean colony count values for TKE 3
V1435 B1 and B2 Mean colony count values for TKE 3
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 6.31 7.56 8.5 8.7 8.85 8.85
INH 6.18 5.51 6.46 6.55 7.46 8.39
M&C 5.19 4.53 4.08 0 0 0
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 289000 3500000 253000000 433000000 700000000 700000000
INH 373000 301000 2080000 2720000 243000000 500000000
M&C 171000 33000 17500 2600 0 0
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 5.46 6.54 8.4 8.64 8.85 8.85
INH 5.57 5.48 6.32 6.43 8.39 8.7
M&C 5.23 4.52 4.24 3.42 0 0
Log Values of V1435 B1 and B2 mean colony count values for TKE 3
V1435 C1 and C2 Mean colony count values for TKE 3
Log Values of V1435 C1 and C2 mean colony count values for TKE 3
Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 5.75 6.86 8.42 8.68 8.85 8.85
INH 5.77 5.48 6.4 6.51 8.04 8.54
M&C 5.19 4.47 4.18 2.25 0 0






















Day 0 Day 3 Day 7 Day 14 Day 21 Day 28
DFC 5.74 6.47 7.55 7.95 7.95 8.25
INH 5.55 5.46 5.67 6.23 7.34 7.12
PAS 5.28 1.83 5.23 6.04 6.24 6.41
CAP 5.6 2.51 0.93 0.9 0 0
LIN 5.36 5.32 4.55 3.68 1.91 0
M&C 5.19 4.47 4.18 2.25 0 0
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